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Abstract
Breast cancer is the most prevalent malignancy in women 
and the second most common cause of cancer-related death 
worldwide. Despite major innovations in early detection and 
advanced therapeutics, up to 30% of women with node-
negative breast cancer and 70% of women with node-positive 
breast cancer will develop recurrence. The recognition that 
breast tumors are infiltrated by a complex array of immune cells 
that influence their development, progression, and metastasis, 
as well as their responsiveness to systemic therapies has sparked 
major interest in the development of immunotherapies. In 
fact, not only the native host immune system can be altered to 
promote potent antitumor response, but also its components 
can be manipulated to generate effective therapeutic 
strategies. We present here a review of the major approaches to 
immunotherapy in breast cancers, both successes and failures, 
as well as new therapies on the horizon.
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cytokines, immunomodulation, immunotherapy, monoclonal 
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Introduction
Over the past half century, advancements in our 
understanding of breast cancer biology have transformed 
the current landscape of disease management, leading to 
improvements in early detection strategies, development of 
breast-conserving surgery techniques, utilization of cytotoxic 
chemotherapy regimens for the treatment of both local and 
metastatic disease, engineering of targeted therapies against 
the hormone pathway and human epidermal growth factor 
receptor 2 (HER2/neu), and employment of hormonally 
directed therapies as a preventive measure [1]. This evolution 
in breast cancer management has led to a one-third reduction 
in mortality since the year 1990 [2,3], yet breast cancer remains 
the most prevalent malignancy in women and second most 
common cause of cancer-related death worldwide [4,5]. 
Disease-related mortality stems primarily from primary 
(de novo) or secondary resistance to available systemic 
therapies. A number of novel approaches are being pursued 
to prevent or circumvent mechanisms of treatment resistance 
and hopefully improve long-term survival. The recognition 
of the role of the immune microenvironment in tumor 
biology has opened the door to an exciting era in oncology 
in which immune components are manipulated to harness 
the inherent ability of the host’s immune system to combat 
malignancy. In this review, immunotherapy approaches for 
the treatment of breast cancers will be explored with a focus 
on both successes and failures as well as new therapies on 
the horizon.
Immune microenvironment in 
breast cancer
Breast tumors are complex systems comprising two primary 
components: the cancer cells typically derived from malignant 
transformation of mammary ductal or lobular cells, and the 
surrounding stromal compartment composed of a variety 
of normal host cells (e.g., fibroblasts, immune cells, and cells 
of the vasculature) and extracellular matrix molecules that 
are conscripted to provide a biochemical and structural 
milieu supportive of tumor development, progression, and 
metastasis [6–10]. One major class of stromal host cells, the 
immune infiltrate, has garnered considerable attention for its 
exploitability in the treatment of many malignancies, including 
breast cancer [11]. 
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Cancer-related inflammation has long been recognized by 
early pathologists, and in 1863 was even postulated to play 
a causative role in oncogenesis [12]. Although malignancy-
associated inflammation is no longer considered a driver of 
tumorigenesis, chronic inflammation increases cancer risk 
and plays a major role in disease pathophysiology [11,13–15]. 
In breast malignancies, this immune infiltrate has been well 
studied. Immunohistochemical analyses in the early-to-mid-
twentieth century showed a correlation between high levels 
of mononuclear immune cell infiltration and better prognosis, 
particularly in the medullary carcinoma histopathologic 
subtype of breast cancer [16,17]. Immunophenotyping studies 
in the 1980s further characterized breast tumor immune 
infiltrates, identifying cells derived from both myeloid (innate) 
and lymphoid (adaptive) lineages, including T lymphocytes 
(primarily CD8+ and CD4+ cells), macrophages, natural killer 
(NK) cells, and B lymphocytes [18,19].
Tumor-infiltrating lymphocytes (TILs) are one of the most 
prominent groups of immune cells in breast cancers [20] and 
consist of predominantly CD8+ cytotoxic T lymphocytes, 
CD4+ T helper lymphocytes, NK cells, and FOXP3+ T regulatory 
cells (Tregs) [21–23]. High levels of CD8+ T-cell infiltration into 
breast tumors have been correlated with improved outcomes 
[24–27], due in part to cancer cell-directed cytotoxicity. 
Similarly, high levels of NK-cell infiltration are associated with 
improved prognosis in breast cancer [28] by mediating CD8+ 
cytotoxic T-lymphocyte activity through the production of 
proinflammatory cytokines such as interferon (IFN)-γ [29–31].
In contrast, high levels of Tregs, which play pivotal roles in 
immune tolerance by suppressing T-cell activation in the 
normal physiologic state and killing or inactivating effector T 
cells in highly inflammatory states [32,33], have been shown 
to promote tumor progression and are associated with poor 
prognosis [34,35]. Furthermore, depletion of Tregs in preclinical 
models by blocking the interleukin-2 pathway has been shown 
to inhibit mammary tumor growth, likely by reprogramming 
the microenvironment from an immunosuppressive one 
to one that is amenable to other immunotherapies (e.g., 
checkpoint inhibitors) [36,37]. This is supported by patient data 
showing that reduction in FOXP3+ regulatory T cells following 
neoadjuvant chemotherapy is associated with pathologic 
complete responses [24]. 
The role of CD4+ T helper lymphocytes in breast cancer is 
less clear, as they have been noted to have both tumor-
promoting and tumor-inhibiting properties, depending on 
their cytokine expression profile and microenvironmental 
context. Proinflammatory (Th1) CD4+ T lymphocytes, which 
typically express IFN-γ, have been shown to promote cytotoxic 
T-lymphocyte activity [38]. In contrast, anti-inflammatory (Th2) 
CD4+ T lymphocytes, which classically express interleukin-4 
(IL-4), have been shown to promote metastasis in preclinical 
models [39,40]. Similarly, the Th17 subset of CD4+ helper T cells 
commonly infiltrates ER– and triple-negative malignancies 
and is associated with poor prognosis [41] owing to its 
promoting effects on cancer cell proliferation, metastasis, and 
chemoresistance [42,43].
Myeloid lineage cells may comprise up to 80% of the immune 
cell infiltrate in breast tumors [44], and consist primarily of 
macrophages, as well as smaller numbers of neutrophils, 
immature granulocytes, and myeloid-derived suppressor 
cells. In a classification scheme akin to that of T helper 
lymphocyte polarization, these macrophages and neutrophils 
are similarly classified as type 1 or 2 based on analogous 
cytokine profiles [21]. Breast tumor-associated macrophages 
(TAMs) are typically M2-polarized, expressing and responding 
to cytokines such as IL-4, and have been shown to promote 
angiogenesis [45], cancer cell intravasation into blood 
vessels [46], diminish responses to cytotoxic chemotherapies  
[39,47–49], and facilitate metastasis. High levels of TAM 
infiltration are associated with poorer outcomes [50,51]. In 
addition to TAMs, other myeloid lineage immune cells have 
also been identified in the breast tumor immune infiltrate. Mast 
cells promote angiogenesis in breast tumors and metastatic 
lesions [52], but their relationship with prognosis varies based 
on breast cancer subtype and tumor stage [53]. Myeloid-
derived suppressor cells (MDSCs) are immature myeloid cells 
that promote an immunosuppressive tumor microenvironment 
through multiple mechanisms, including expression of Th2-
type cytokines, production of reactive oxygen species, and the 
metabolism of arginine [54].
The role of the B-lymphocyte infiltrate in breast malignancies 
is less understood. Studies in medullary carcinoma of 
the breast, in which high levels of B cell infiltration into 
tumors are associated with better outcomes, suggest that 
B lymphocytes undergo clonal proliferation and affinity 
maturation within primary tumors against both host- and 
tumor-directed antigens, which ultimately lead to activation 
of apoptosis [55,56]. These data are further supported by 
studies in intraductal carcinomas, in which similar results were 
observed [57,58].
Immunotherapy in breast cancer
The recognition of an inflammatory infiltrate in solid tumors 
and our growing understanding of the varied functions of 
tumor inflammation have raised the question of whether 
the immune system can be effectively exploited to promote 
tumor destruction. This led to the birth of the field of cancer 
immunotherapy, which is broadly defined as any therapeutic 
approach that utilizes a specific component of the immune 
system or enhances or augments the intrinsic host immune 
response to treat malignancy [59]. Two fundamental principles 
have been recognized as guiding the development of 
cancer immunotherapy. They are as follows: (1) both the 
innate and adaptive immune systems play an important 
role in cancer cell immunosurveillance and destruction by 
utilizing the same mechanisms in play during infection with 
foreign pathogens and (2) oncogenesis and progression 
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administration of other recombinant interferons were similarly 
unsuccessful in breast cancer [74–76], likely owing to the lack 
of other cytokines and chemokines present in the original 
preparations. The addition of IL-2 to IFN therapy has also been 
ineffective [77].
Limiting factors in the successful application of cytokines 
include tachyphylaxis with subsequent administrations, 
ineffective stimulation of T-cell-mediated tumor-directed 
responses, and significant dose-limiting side effects with 
systemic therapy, including overwhelming fatigue and severe 
cytokine release syndromes. Strategies for improving immune 
activation and decreasing the systemic effects of cytokine 
therapy are underway in preclinical models and early-phase 
clinical trials. These approaches include intra-tumoral injection 
of cytokines [78], combination of cytokine therapy with 
systemic therapy [79,80], gene therapy with adenovirus vectors 
and oncolytic viruses expressing cytokines and chemokines 
under the direction of tissue-specific promotors [81,82], 
tumor-targeted super-antigen therapy utilizing components of 
bacterial toxins [83], and cytokine-antibody fusion molecules 
(reviewed [84]). 
Systemic administration of growth factors has similarly 
found limited use for inducing remission of breast cancer. 
However, in the management of chemotherapy-induced 
toxicities, growth factors, particularly granulocyte colony-
stimulating factor (G-CSF) and granulocyte-macrophage 
colony-stimulating factor (GM-CSF), are routinely used for the 
prevention of neutropenia [85,86]. Another growing niche for 
growth factors in breast cancer therapy is as adjuvants to other 
immunotherapies, such as cancer-directed vaccines.
Disruption of both cytokine and growth factor signaling 
pathways has also been a major area of immunotherapy 
research. Neutralizing antibodies against cytokines and certain 
chemokines have been shown to be effective in preclinical 
models and are currently in early-phase clinical trials with 
results forthcoming [87].
Immunomodulatory agents
Immunomodulatory agents are chemicals capable of altering 
immune responses, angiogenesis, and cancer cell proliferation. 
The earliest immunomodulatory agents focused on generating 
potent innate immune responses to stimulate lasting cytotoxic 
CD8+ T-cell effector functions through the activation of Toll-
like receptors (TLRs). TLR agonists are nonspecific molecules 
capable of binding these pattern-recognition receptors, 
thereby activating transcriptional pathways regulated by 
nuclear factor (NF)-κB and activating complement pathways, 
opsonization, and phagocytosis, inducing apoptosis and 
stimulating cytotoxic T-cell responses [88]. 
Preclinical animal studies in the 1960s and 1970s showed that 
administration of polyadenylic-polyuridylic acid (poly A:U), a 
double-stranded RNA polynucleotide that stimulates TLR3, 
after mastectomy in spontaneous tumor and orthotopic 
occurs through the selection and outgrowth of cancer 
cells with low immunogenicity and the generation of an 
immunosuppressive microenvironment [60]. Therapeutic 
strategies have therefore focused on activating both innate 
and antibody-mediated immune responses to induce cancer 
cell death. These technologies include cytokines and growth 
factors, immunomodulatory agents, alteration of the tumor 
microenvironment, passive immunization with monoclonal 
antibodies, bispecific and multispecific antibodies, checkpoint 
inhibitors, vaccines, oncolytic viruses, and adoptive T-cell 
transfer [61,62] (Table 1).
Cytokines and growth factors
Cytokines and growth factors are secreted or membrane-
bound proteins produced by both innate and adaptive immune 
cells in response to a stimulus (e.g., a pathogen or cancer 
cell). They exert pleiotropic effects on components of the 
immune system by binding to specific cytokine receptors on 
many different effector cells, initiating signaling pathways to 
modulate cell trafficking, survival, proliferation, maturation, 
and function, thereby promoting or inhibiting tumor-directed 
responses while maintaining immunologic homeostasis and 
self-tolerance. These molecules can also exert effects on 
cancer cells, contributing to their proliferation, invasiveness, 
intravasation, metastasis, and chemoresistance [63–66]. 
Activating or inhibiting these signaling pathways has been a 
major focus in immunotherapy research. 
Cytokine therapy is a therapeutic strategy that was first 
recognized in the late 1800s when inoculation of highly 
virulent streptococcal cultures was shown to induce remission 
in patients with inoperable, metastatic sarcoma [67]. Later 
successes using systemic IL-2 for the treatment of metastatic 
renal cell carcinoma and metastatic melanoma [68,69] paved 
the application of cytokine therapy to other malignancies. 
However, in breast cancer, systemic cytokine treatment has 
been less successful for the treatment of breast cancer. IFNα 
was the first cytokine noted to have a potentially beneficial 
effect in the treatment of breast cancer. In 1980, Gutterman 
et al. administered partially purified IFNα derived from 
human buffy coat preparations to 17 patients with recurrent, 
metastatic breast cancer and noted 7 patients had tumor 
regression with 6 patients achieving partial remission as 
defined by >50% objective decrease in tumor size [70]. A 
subsequent Phase II study in patients with recurrent metastatic 
breast cancer who had not received cytotoxic salvage 
chemotherapy was conducted to determine the efficacy 
of similarly derived, partially purified IFNα preparations as 
monotherapy, and it was confirmed that systemic cytokine 
administration was indeed capable of inducing a partial 
objective response in 5 of 23 patients with breast cancer 
and a measurable response in 6 of 23 patients [71]. However, 
subsequent Phase II trials utilizing purified, recombinant IFNα 
did not yield significant tumor responses in the treatment 
of metastatic breast cancers [72,73]. Studies with systemic 
Nakasone ES, Hurvitz SA, McCann KE. Drugs in Context 2018; 7: 212520. DOI: 10.7573/dic.212520 4 of 21
ISSN: 1740-4398
REVIEW – Harnessing the immune system in the battle against breast cancer drugsincontext.com
Table 1. Strategies for activation of the immune system against breast cancer.
Class Mechanism Examples
Cytokines Bind to cytokine receptors to initiate cell signaling 
pathways and stimulate immune cell trafficking and 
effector function
Interleukin-2
Interleukin-12
Growth factors Increase number of circulating granulocytes G-CSF
GM-CSF
Toll-like receptor 
agonists
Bind TLRs to activate antigen-presenting cells 
(dendritic cells) to upregulate expression of 
cytokines and co-stimulatory molecules to attract 
and stimulate effector immune cells (cytotoxic T 
lymphocytes)
Polyadenylic-polyuridylic acid (Poly A:U) 
Polyinosinic-polycytidylic acid (Poly I:C)
Immune checkpoint 
inhibitors
Antibody to CTLA-4, PD-1, or PD-L1 molecules 
releases T cells from inhibitory signals, thereby 
unleashing cytotoxic T-cell activity
Ipilimumab (CTLA-4 antibody)
Nivolumab (PD-1 antibody)
Pembrolizumab (PD-1 antibody)
Atezolizumab (PD-L1 antibody)
Avelumab (PD-L1 antibody)
Durvalumab (PD-L1 antibody)
Bispecific, multispecific
antibodies
Simultaneously interact with a cancer-specific 
epitope and stimulatory molecule(s) on effector 
cell(s)
HER2/CD3 bispecific antibodies
Adoptive cell transfer Infusion of T cells stimulated or engineered to have 
antitumor effector functions
Chimeric antigen receptor (CAR) T cells 
expressing HER2/neu
Oncolytic viruses Viruses with specific tropism for cancer cells that 
induce cancer cell death and activate tumor-
directed immune responses
JX-594 (pexastimogene devacirepvec) 
vaccinia poxvirus expressing GM-CSF)
Vaccines Active immunization against tumor-specific 
antigens
Nelipepimut-S vaccine against HER2/neu 
Therapeutic strategies to harness the innate and adaptive immune system against breast cancer cells include nonspecific 
immune system stimulation with cytokines, growth factors, and Toll-like receptor agonists, release of T cells from inhibitory 
PD-L1 signals, use of antibodies to transmembrane tyrosine kinase receptor HER2 to tag HER2+ breast cancer cells for immune-
mediated destruction, stimulation of T cells within the HER2+ breast tumor microenvironment, active vaccination or in vitro 
reprogramming of T cells against HER2/neu, and injection of oncolytic viruses. See text for details.
G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HER2, human 
epidermal growth factor receptor 2; TLR, Toll-like receptor.
transplant models of breast cancer significantly delayed 
relapse [89,90]. Furthermore, administration of poly A:U to 
newborn mice that developed spontaneous mammary tumors 
resulted in reduced incidence of malignancy [91]. This agent 
entered clinical trials in France during the 1980s [92–94] as 
an adjuvant therapy in surgically resectable breast cancer 
and showed significantly improved overall survival in node-
positive patients. Head-to-head studies comparing adjuvant 
cytotoxic therapy with cyclophosphamide, methotrexate, 
and fluorouracil (CMF) to adjuvant poly A:U demonstrated 
a significantly improved disease-free survival and reduced 
incidence of metastasis in patients with limited disease (i.e., 
1–3 positive nodes) with positive TLR3-expression [94]. Similar 
results were obtained when a combination of adjuvant 
locoregional radiation and poly A:U therapy was compared 
to adjuvant chemotherapy with CMF [95,96]. Despite these 
promising results, adjuvant poly A:U has not been approved for 
the treatment of breast cancer, likely owing to its applicability 
to a very small population of women with limited disease. 
Another TLR3 agonist, polyinosinic-polycytidylic acid (poly 
I:C), has been shown to induce tumor necrosis [97], reduce 
metastases [98], and induce long-lasting CD8+ T-cell responses 
in combination with CpG oligodeoxynucleotides (a TLR9 
agonist) [99] in preclinical models. The use of poly I:C has been 
limited owing to significant toxic effects, specifically severe 
cytokine release syndromes. 
Cytokine-release syndromes with the systemic administration 
of TLR agonists have largely limited their use as monotherapy 
in clinical scenarios. However, research into modifying 
delivery and structural components to reduce their side-
effect profiles and their use as immunotherapeutic adjuvants 
is ongoing. Several TLR agonists, including monophosphoryl 
lipid A and OK-432 (TLR4 agonists) [100], poly ICLC (TLR3 
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Preventing myeloid cell recruitment is another strategy 
for interfering with TAM function. Studies in murine 
models of breast cancer have shown that the interaction 
between the chemokine CCL2 (C-C motif chemokine 
ligand 2) and its receptor CCR2 (C-C chemokine receptor 
2) promotes recruitment of TAMs into tumors and 
metastatic sites, promoting tumor angiogenesis, cancer 
cell extravasation, and metastasis, and inhibiting CCL2/
CCR2-mediated recruitment delays relapse, improves 
survival, and decreases metastatic burden [49,112,113]. 
Despite promise as a therapeutic strategy in preclinical 
models, CCL2 antagonism has had limited success. The 
anti-CCL2 monoclonal antibody carlumab, while generally 
safe in a Phase I trial for advanced solid malignancies [114], 
ultimately did not demonstrate in vivo ability to block the 
CCL2/CCR2 pathway or exert antitumor effects in metastatic 
castrate-resistant prostate cancer, resulting in suspension 
of further planned studies with carlumab [115]. Similar 
results were obtained when an antibody against CCR2 
was used in patients with advanced malignancy and bony 
metastases [116].
Immune checkpoint Inhibition
The detection of immune checkpoints that prevent 
autoimmunity when normal immune responses are triggered, 
the identification of specific cell types and molecules 
involved in this process, and the understanding of roles 
that each of these cells and molecules play in promoting 
an immunosuppressive tumor microenvironment have led 
to the development of blocking monoclonal antibodies 
aimed at improving the host immune response to cancer. 
By antagonizing these molecules, potent anticancer T-cell 
responses may be reactivated. This class of therapies, called 
immune checkpoint inhibitors, has revolutionized the 
treatment of various malignancies, including malignant 
melanoma, renal cell carcinoma, non-Hodgkin’s lymphoma and 
smoking-associated non-small-cell lung cancer [117]. 
Immune checkpoint inhibitors function by interfering with two 
separate T-cell inhibitory pathways: cytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4) and programmed death 1 
(PD-1). Traditionally, activation of T-cell responses requires 
two functional synapses between antigen-presenting cells 
(APCs) and T cells: (1) binding of an antigen-containing major 
histocompatibility complex (MHC) molecule with a T-cell 
receptor (TCR) and (2) binding of the APC cell surface molecule 
B7 to the T-cell co-stimulatory molecule CD28. These two 
interactions result in upregulation of IL-2 expression by the 
activated T cell, leading to proliferation and stimulation of 
effector function. CTLA-4 and PD-1 are cell surface molecules 
expressed by T cells that are structurally homologous to CD28, 
but which act as co-inhibitory molecules when bound to their 
respective ligands. CTLA-4 acts a co-inhibitory signal to prevent 
IL-2 expression by T cells when complexed with B7 on an APC. 
PD-1, which is expressed on a wide variety of cells that include 
agonist that is a compounded mixture of poly I:C and poly-
lysine), and CpG oligodeoxynucleotide (TLR9 agonist), 
are being studied as vaccine enhancers. They are also 
being studied as adjuncts to systemic or radiation therapy 
[99,101], as well as local therapeutics, for example, topical 
imiquimod (TLR7 agonist) as therapy for skin metastases in 
breast cancer [102].
Other immunomodulatory agents inhibit immunosuppressive 
molecules. For example, indoleamine 2,3-dioxygenase 
(IDO) is an enzyme that metabolizes tryptophan to produce 
metabolites that stimulate the expansion of Treg populations, 
thereby suppressing cytotoxic T-cell activity [103]. In a 
transgenic model of breast cancer, indoximod (an inhibitor of 
IDO) in combination with cytotoxic systemic therapy induced 
tumor regression [104]. These studies have resulted in the 
initiation of clinical trials utilizing indoximod with cytotoxic 
therapy for the treatment of breast cancer [105,106].
Altering the tumor microenvironment
The complexity of the tumor microenvironment and the many 
roles its constituents play in breast cancer development, 
progression, metastasis, and response to chemotherapeutic 
agents has altered the tumor microenvironment a particularly 
exciting area of research. Efforts to target the immune-
stroma include those aimed at preventing recruitment, 
altering polarization, inhibiting activation, and depleting 
certain tumor-infiltrating immune cells that may contribute 
to tumor pathogenesis. TAMs are of particular interest, in part 
because they can be polarized by Th2 cytokines to adopt an 
M2 phenotype with tumor-promoting, immunosuppressive 
functions [107]. Moreover, they comprise a significant 
proportion of tumor-infiltrating leukocytes in breast 
cancers, correlating with poor prognosis [108,109]. Colony-
stimulating factor-1 (CSF-1) is a regulatory growth factor 
crucial for macrophage survival, proliferation, and effector 
functions [110], and neutralizing this molecule or its cognate 
receptor CSF-1R has been a particularly attractive approach 
to targeting TAMs. Indeed, blocking antibodies against 
CSF-1R leads to the depletion of TAMs and FOXP3+ Treg 
populations, an increase in the ratio of CD8+:CD4+ T cells, 
and delays in tumor growth in TAM-rich tumor models [111]. 
Neutralizing antibodies against CSF-1 in combination with 
paclitaxel effectively reduces metastatic burden in a mouse 
model of luminal B breast cancer in part by augmenting CD8+ 
T-cell activity [109]. There are currently three monoclonal 
antibodies targeting CSF-1R in early-phase trials: emactuzumab 
administered alone or in combination with paclitaxel 
(NCT01494688) or in combination with the PD-L1 inhibitor 
atezolizumab (NCT02323191) for unspecified advanced solid 
tumors, LY3022855 as monotherapy for unspecified treatment-
refractory solid tumors (NCT01346358) or specifically for 
treatment-refractory breast or prostate cancer (NCT02265536), 
and AMG 820 as monotherapy in unspecified advanced solid 
malignancies (NCT01444404).
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leukocytes and parenchymal cells, binds to its ligands PD-L1 
and PD-L2 on APCs. Expression of CTLA-4 depends on potency 
of the immunologic trigger, while expression of PD-1 depends 
on the duration of the immunologic response and is associated 
with T-cell exhaustion. Increased expression of CTLA-4 and 
PD-L1 in tumor tissues allows for the evasion of tumor-directed 
T-cell responses [118,119] (Figure 1).
There are currently six immune checkpoint inhibitors with 
FDA-approved indications for clinical use: the CTLA-4 blocking 
antibody ipilimumab, the PD-1 blocking antibodies nivolumab 
and pembrolizumab, and the PD-L1 neutralizing antibodies 
atezolizumab, avelumab, and durvalumab. While there are 
very rare indications for the use of checkpoint inhibitors in 
breast cancer treatment, there is evidence to suggest that 
these therapies may be effective, particularly in breast cancer 
subtypes with large immune infiltrates, including HER2+ 
and TNBC. These data include increased mutational rates 
resulting in a larger burden of tumor-associated neoantigens 
[120], recruitment of tumor-infiltrating lymphocytes [121], 
and PD-L1 expression [122,123]. Indeed, several early-
phase trials are underway with checkpoint inhibitors in 
Figure 1. Immune checkpoint inhibitors.
A. Normal T-cell activation requires two functional synapses: binding of an antigen-
containing MHC molecule with a T-cell receptor and binding of the co-stimulatory 
molecule CD28 found on T cells with B7, found on antigen-presenting cells. B. CTLA-4 is 
a co-inhibitory molecule present on normal T cells. Binding of CTLA-4 with B7 inhibits 
activation of T cells. Blocking antibodies against CTLA-4 prevents its binding with B7, 
thereby allowing for CD28 interaction with B7 and T-cell activation. C. PD-1 is a  
co-inhibitory molecule present on normal T cells. Its ligand, PD-L1, is upregulated in  
cancer cells. Blocking antibodies against either PD-1 or PD-L1 allow for T-cell activation.
monotherapy (KEYNOTE-012 [124] and KEYNOTE-086 
[125] evaluating pembrolizumab for TNBC, KEYNOTE-028 
evaluating pembrolizumab for PD-L1+ ER+ HER2– breast cancer 
[126], and the JAVELIN trial evaluating avelumab for locally 
advanced or metastatic breast cancers) or in combination with 
cytotoxic therapy (nanoparticle albumin-bound paclitaxel 
with atezolizumab [127–129] and the I-SPY-2 trial evaluating 
paclitaxel with or without pembrolizumab for 12 weeks 
followed by doxorubicin and cyclophosphamide for 8–12 
weeks [130]). Preliminary results from early-phase trials with 
pembrolizumab [125] or atezolizumab [131] monotherapy for 
TNBC indicate that patients who initially respond to therapy 
have durable treatment responses. It does, however, appear 
that these responses are dependent on high levels of tumor-
infiltrating lymphocytes [125,131], and this response wanes with 
increasing exposure to systemic cytotoxic chemotherapy [132] 
(Table 2).
Other immune checkpoints have also been identified, including 
two inhibitory signals that are co-expressed by activated T cells 
and upregulated with PD-1 on chronically stimulated tumor-
infiltrating lymphocytes – lymphocyte activation gene 3 (LAG3) 
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[133] and T-cell immunoglobulin and mucin domain 3  
(TIM-3) [134] – and a co-stimulatory receptor in the TNF family 
of receptors called OX40 that is capable of promoting CD8+ 
T-cell proliferation and activity, inhibiting generation of Tregs, 
and expanding memory CD4+ T-cell populations [135]. Early-
phase clinical trials with these agents are underway and have 
been reviewed elsewhere [136].
Bispecific and multispecific antibodies
In addition to releasing the brakes on T-cell responses, 
antibodies can be engineered to directly activate potent 
tumor-directed responses at the site of the target. One such 
tool is the bispecific antibody (BsAb), which simultaneously 
interacts with cancer cell-specific epitopes and a stimulatory 
molecule on an effector cell population. This molecule creates 
an immunologic synapse capable of activating a potent innate 
or adaptive immune response [137]. In breast cancer, several 
iterations of BsAbs have been generated. HER2 is particularly 
attractive as the target for the tumor-oriented specificity and 
is frequently used [138,139]; however, other targets have also 
been employed, including epithelial cell adhesion molecule 
(EpCAM) [140,141] and epithelial growth factor receptor (EGFR) 
[142]. The initial effector cell target was the macrophage 
CD64 (Fcγ receptor I) to activate macrophage-mediated 
killing. Early-phase clinical trials using these antibodies were 
largely unsuccessful for several reasons, including the need 
for systemic cytokine or growth factor administration to 
boost macrophage responsiveness in some instances and the 
associated side-effect profile of these enhancing therapies, 
induction of autoantibodies against the administered BsAbs, 
and a lack of objective clinical response [143–146].
Although macrophage activation has had a limited effect on 
tumor-directed immunity in humans, T-cell activation has 
been a more promising area of research. Newer generations of 
BsAbs have effector cell specificities targeting CD3 on T cells 
[147] and elicit potent CD8+ cytotoxic T-cell activity both in vitro 
and in vivo in preclinical models of breast cancer [139,148–151]. 
Furthermore, pre-stimulating and arming T cells with BsAbs 
[152], as well as combining them with checkpoint inhibitors, are 
promising areas of further research. 
Another approach to immune activation has been the use of 
multispecific antibodies, which are capable of binding to three 
or more epitopes and have also been utilized to activate tumor-
directed immune responses. For example, the trifunctional 
monoclonal antibody ertumaxomab, which recognizes HER1, 
CD3, and Fcγ receptor types I and III, has been shown to induce 
lysis of human breast cancer cells in vitro [153] and is capable of 
eliciting a strong immune response in humans as evidenced by 
early-phase clinical trials [154]. 
Vaccines and oncolytic viruses
Cancer vaccines are a form of active immunization against 
tumor-specific antigens designed to stimulate immune 
responses directed against cancer cells, rather than prevent 
disease as in the canonical sense of the term ‘vaccine’. Many 
different approaches have been utilized to generate cancer 
vaccines, including whole tumor cells, whole cell lysates, 
peptides, glycosylated antigens, nucleic acids, and viruses 
[155,156]. When these vaccines are delivered, they elicit innate 
immune responses resulting in phagocytosis and processing of 
antigens by APCs. APCs insert these antigens into major MHC 
class I molecules to trigger T-cell-mediated cytotoxicity or MHC 
class II molecules to trigger T helper cell responses and humoral 
immunity. Adjunct molecules can also be used to induce more 
potent and durable responses [157,158].
In breast cancer, the most commonly employed epitope is 
HER2. While many different platforms have been used to 
generate anti-HER2 vaccines, the most promising is NeuVaxTM, 
a synthetic peptide analogue of HER2 called nelipepimut-S, 
which is capable of binding to CD8+ cytotoxic T cells and 
is administered with the immune adjuvant GM-CSF [159]. 
In Phase I and II trials, nelipepimut-S in combination with 
GM-CSF following surgical intervention with adequate 
lymph node dissection and completion of neoadjuvant or 
adjuvant radiation or chemotherapy improved disease-free 
survival [160], although results from a Phase III trial were 
less optimistic, with the study being suspended for futility 
following an interim safety and futility analysis. Several 
other trials with nelipepimut-S are in progress, including 
combination therapy with trastuzumab for ER–/PR–, lymph 
node-negative HER2+ or lymph node-positive HER2+ disease 
following standard-of-care therapy (NCT01570036), in high-
risk HER2+ breast cancer populations (NCT02297698), and 
in ductal carcinoma in situ (NCT02636582). Other driver 
mutation-targeted vaccines currently in early-phase trials 
include AVX901, a virus-like replicon particle based on an 
attenuated Venezuelan equine encephalitis virus engineered 
to express HER2 [161] and INO-1400, a synthetic DNA vaccine 
targeting the hTERT oncogenic protein with or without a 
plasmid expressing IL-12 (NCT02960594). Vaccines against 
carbohydrates, which are expressed in a wide variety of 
solid tumor types, including breast cancer, are also being 
studied. One such example is MAG-Tn3, a multiple antigenic 
glycopeptide vaccine conjugated with tetanus toxoid that 
targets the universal carbohydrate tumor antigen Tn (α-D-N-
acetylgalactosamine linked with serine or threonine), which is 
highly expressed in breast tumors [162]. It is currently in Phase 
I evaluation for patients with localized breast cancer at high 
risk for relapse (NCT02364492). Another example is OPT-822/
OPT-821, a synthetic glycoprotein containing the universally 
expressed tumor carbohydrate Globo H bound to the carrier 
protein keyhole limpet hemocyanin (KLH). In an international, 
randomized, double-blind, placebo-controlled Phase II/III 
trial, patients who mounted an IgG response detectable at 
titers of ≥1:160 to the vaccine showed significant progression-
free survival (HR, 0.71 [95% CI, 0.52–0.97] P=0.029) and 
interim overall survival (HR, 0.57 [95% CI, 0.33–0.97] P=0.04 
for OS) [163].
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Oncolytic viruses are genetically engineered viruses with 
cancer cell-specific tropism resulting in the infection and 
destruction of cancer cells while sparing host tissues. These 
viruses induce cancer cell death through multiple mechanisms, 
including virus-mediated cancer cell cytotoxicity, infection 
of surrounding endothelial cells resulting in destruction of 
tumor vasculature, and activation of tumor-directed immune 
responses [164,165]. Oncolytic virus-based vaccines that are 
approved for other malignancies are now in early-phase trial 
for the treatment of breast cancer. These include talimogene 
laherparepvec (T-vec), approved for use in locally recurrent, 
non-resectable melanoma, and JX-594 (pexastimogene 
devacirepvec), which has an FDA orphan drug designation for 
hepatocellular carcinoma. T-vec is a herpes simplex virus-1 
(HSV-1) with deletions of ICP34.5 and ICP47, virulence factors 
that play critical roles in viral replication and inhibition of 
host immune responses, and engineered to produce GM-CSF 
[166]. It is currently in clinical trial as monotherapy for the 
treatment of locally recurrent breast cancer (NCT02658812), 
as neoadjuvant therapy in TNBC (NCT02779855), and in 
combination with the PD-L1 inhibitor atezolizumab for 
metastatic TNBC (NCT03256344). JX-594 is a replication-
competent vaccinia poxvirus with deleterious mutations in its 
viral thymidine kinase gene, resulting in tropism for cancers 
with overexpression of thymidine kinase, and which expresses 
human GM-CSF to stimulate antitumor immune responses 
[167]. It is currently in trial as a combination therapy with 
metronomic cyclophosphamide in advanced breast cancer in 
France (NCT02630368).
Adoptive transfer of immune cells
Adoptive transfer is the collection and ex vivo manipulation  
of immune cells to stimulate antitumor activity, with reinfusion 
of these cells back into patients [168]. Evidence that adoptive 
transfer had potential as an effective anticancer therapy was 
first shown in syngeneic murine tumor transplant models 
in 1955 [169], with subsequent successes in rodent sarcoma 
and lymphoma models in the 1970s [170–172]. However, 
it was a series of studies in the early 1980s that provided 
the groundwork for the development of adoptive transfer 
technologies. Peripheral blood lymphocytes (PBL) collected 
from healthy donors and grown in the presence of PBLs 
from patients with malignancy were capable of lysing both 
previously cultured and freshly harvested human cancer 
cells [173]. Similar results were obtained using PBLs collected 
from patients with malignancy [174] and tumor-infiltrating 
leukocytes [175] expanded ex vivo with IL-2. Adoptive 
transfer of PBLs collected from cancer patients that were 
expanded ex vivo (lymphokine-activated killer cells) and 
coadministered with IL-2 resulted in regression of metastatic 
disease and improved survival in preclinical models of 
metastatic melanoma and colon adenocarcinoma [176–178], 
providing the impetus for further research and initiation of 
clinical trials [179–181].
After early clinical successes were observed in melanoma and 
renal cell carcinoma with the combination of lymphokine-
activated killer (LAK) cells and IL-2, efficacy of this regimen in 
other malignancies was evaluated, including breast. However, 
this therapeutic strategy ultimately yielded minimal responses 
in advanced breast tumors, as well as most other epithelial 
malignancies evaluated [182,183]. In vitro three-dimensional cell 
culture models of breast cancer data suggested that the lack of 
response to adoptive transfer therapies was due to decreased 
ability of immune cells to infiltrate and adhere to tumors and 
was also related to the fact that environmental signals inhibited 
the proliferation of infiltrating leukocytes. These data provided 
a basis for understanding the lack of clinical efficacy [184,185]. 
While adoptive transfer of PBLs and TILs expanded ex vivo 
has largely remained unsuccessful in breast cancer, studies 
focusing particularly on TILs have shifted toward identifying 
and expanding effector cells in TIL populations that recognize 
specific, immunogenic, non-synonymous mutations that can 
be used for adoptive transfer. A particularly effective strategy 
for identifying these cells relies on the use of whole exome 
sequencing to detect clonal mutations in whole tumor tissue 
samples, inducing expression of oligopeptides bearing these 
mutations by immune cells (typically B cells or dendritic cells) 
ex vivo, coculturing these antigen-presenting cells with TILs, 
and sorting activated lymphocytes by flow cytometry for 
confirmation of cytotoxic activity and clonal expansion [186,187]. 
A recent case report showed that combining this strategy with 
pre-transfer lympho-depleting chemotherapy and a single dose 
of the immune checkpoint inhibitor pembrolizumab was capable 
of generating durable antitumor immunologic responses 
and measurable regression in a patient with metastatic, 
chemotherapy-refractory ER+, HER2– breast cancer [188].
A more common approach to adoptive therapy technologies 
that is rapidly becoming a major area of research is the genetic 
engineering of T cells capable of producing highly specific 
and potent antitumor responses. Techniques for rapidly 
generating T-cell specificity that allows for immediate initiation 
of downstream cell signaling cascades and effector functions, 
so-called armed T cells, are the transduction of retroviruses or 
lentiviruses encoding bispecific and multispecific antibodies 
[139,149,150] and chimeric antigen receptors (CARs). Chimeric 
antigen receptors are genetically engineered hybrid T-cell 
receptors typically consisting of a single-chain variable 
fragment (scFv) of the antibody-based B-cell receptor to confer 
antigen specificity plus the T-cell receptor CD3ζ transmembrane 
and intracellular signaling domains linked to one or more 
intracellular co-stimulatory domains (Figure 2) [189]. While 
many breast cancer-specific antigens have been identified, 
HER2 is again the most frequently targeted antigen for CAR 
design. T cells armed with HER2-specific CARs demonstrate 
potent in vitro T-cell-mediated cancer cell cytotoxicity and are 
capable of inducing regression of tumors in rodent mammary 
tumor models [190–192]. As these T-cell responses typically 
wane with time, other approaches have been utilized to 
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prolong T-cell activity. For example, transposon technology has 
been used to express a HER2 CAR in Epstein–Barr virus (EBV)-
specific cytotoxic T lymphocytes, which proliferate in response 
to chronic host infection with EBV, thereby affording continued 
in vivo T-cell expansion while redirecting effector activity 
toward HER2+ cancer cells [193]. There are currently two early-
phase clinical trials assessing safety and efficacy of adoptive 
transfer of autologous HER2 CAR-expressing T cells in breast 
cancer patients (NCT01935843, NCT02547961).
Adoptive transfer of other immune cell populations, particularly 
NK cells and dendritic cells (DCs), has also been an active area of 
research. NK cells act through multiple mechanisms, including 
receptor-mediated cytotoxicity, ADCC, activation of death 
receptor-mediated apoptotic pathways, and expression of 
cytokines that promote adaptive immune responses [194].  
NK cells collected from circulating peripheral blood 
mononuclear cells (PBMCs) in breast cancer patients exert 
potent cancer cell-directed cytotoxicity in vitro and significantly 
reduce cancer cell engraftment and growth in murine 
xenograft models of breast cancer metastasis [195]. NK cells 
can also be modified to express tumor antigen-directed CARs, 
leading to potent receptor-mediated cytotoxicity. For example, 
a modified NK-92 cell line derivative that expresses a CAR with 
an scFv targeting HER2 and the CD3ζ and CD28 co-stimulatory 
signaling domains is capable of potent and selective killing 
of cancer cells expressing HER2 in vitro and, upon adoptive 
transfer, is capable of homing to orthotopic HER2+ murine 
mammary tumors and reducing metastasis formation in murine 
models of pulmonary metastasis [196]. Another modification 
of the NK-92 cell line designed to simultaneously express the 
cytokine IL-15 and a CAR with an scFv targeting EpCAM and 
the CD3ζ and CD28 co-stimulatory signaling domains was also 
shown to selectively kill breast cancer cells in vitro [197]. 
Dendritic cells are the primary innate immune cell population 
responsible for activating adaptive T-cell-mediated cytotoxic 
and humoral responses. They are typically derived from 
the ex vivo differentiation of PBMCs, bone marrow-derived 
monocytes, or CD34+ hematopoietic stem cells with GM-CSF 
and IL-4 with or without TNF-α. In breast cancers, several 
mechanisms have been employed to load DCs with antigens, 
including infusion with whole tumor lysates [198], incubation 
with oligopeptides homologous to portions of known tumor 
antigens [199,200], transduction of viral vectors engineered to 
express tumor antigens [201,202], and fusion of activated DCs 
with cancer cells [203]. Despite their ability to activate T cells in 
vitro and promising evidence in murine breast cancer models, 
DC-based immunotherapies in monotherapy have been largely 
unsuccessful in early-phase trials [199,200,202]. 
Strategies employed to enhance the effects of adoptive transfer 
with DCs (so-called DC vaccines) are combining DC infusion 
with cytokine-induced killer cells (CIKs) and depleting Treg 
populations. CIKs are a heterogeneous population of MHC 
nonrestricted lymphocytes, expanded in vitro, that typically 
express both CD3 and CD56, but also include small subsets 
of CD3–, CD56+ NK cells and CD3+, CD56– T cells. All three of 
these subsets are activated by DCs, and those CIKs with dual 
expression of CD3 and CD56 are capable of both NK and 
antigen-specific T-cell activity when activated [204]. Indeed, 
in a Phase I/II trial, combining autologous transfer of ex vivo-
selected and expanded DC/CIK with high dose chemotherapy 
improved both progression-free and overall survival in patients 
with metastatic breast cancer [205]. Promising results have also 
been seen with daclizumab, a monoclonal antibody directed 
against CD25, that downregulates expression of both CD25 and 
FOXP3 in Tregs, resulting in reprogramming of these immune 
cells and allowing for priming and boosting of CD8+ T-cell 
activity when combined with DC-based adoptive transfer in 
patients with metastatic breast cancer [37].
Challenges and future perspectives
Breast tumors are infiltrated by a diverse array of immune cells 
that shape and influence the progression of this heterogeneous 
group of malignancies. Increasing understanding of the 
basic biological mechanisms of this complex immune 
Figure 2. General structure of chimeric antigen 
receptor.
The second generation chimeric antigen receptor 
(pictured) comprises three primary components: a single 
chain variable fragment (scFV) that recognizes a specific 
tumor antigen (e.g., HER2), an intracellular co-stimulatory 
domain (commonly CD28), and the intracellular CD3ζ 
chain. Third generation CARs may have a second 
co-stimulatory domain between the second generation 
co-stimulatory domain and the CD3ζ chain (typically 
4-1BBB or OX40). 
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microenvironment and the recognition that components of the 
immune system and their effector functions can be augmented 
and potentiated to effectively target and destroy breast tumors 
has driven the rapid development and evolution of breast 
cancer immunotherapies.
Increasing sophistication of immune system-based 
technologies has resulted in enhanced specificity, leading to 
better side-effect profiles and improved outcomes. However, 
several challenges remain. Tumors have consistently found 
methods to adapt and develop resistance against cytotoxic 
chemotherapeutics, and emerging evidence indicates that 
this is true for immunotherapies as well [206]. Given the 
complexities of the immune system, combination therapies 
will need to be employed to circumvent immune-mediated 
resistance. These strategies include simultaneously combining 
immunotherapy with cytotoxic agents, augmenting 
both the innate and adaptive immune systems, tandem 
immunotherapies, and combining immune checkpoint 
inhibition with DC-based vaccines [207], among others. 
Combinatorial methods will necessarily need to be approached 
with caution, as global activation of the immune system has 
the potential for serious adverse effects, including severe 
cytokine release syndromes. Therefore, reliable mechanisms 
for efficiently and specifically activating or disinhibiting 
multiple tumor-directed responses in vivo will need to be 
further cultivated. Finally, while many of these approaches are 
technically feasible, immunotherapies are often cost prohibitive 
and will require development of streamlined, high-throughput 
technologies, particularly for those therapies that rely on 
adoptive transfer.
Despite these challenges, rapid advances in breast cancer 
immunotherapies are showing significant promise for the 
treatment of many subtypes, including TNBCs. In TNBCs, TIL 
infiltration correlates positively with response to immune 
checkpoint inhibitors, and these responses are long lasting 
[131,208]. As this response appears to be more effective when 
immunotherapy is administered as part of first-line therapy 
[126] and with the identification of biomarkers for response to 
immunotherapy, strategies harnessing the immune system may 
alter the landscape of current approaches for TNBCs.
Disclosure and potential conflicts of interest: The authors have declared that there are no conflicts of interest. The International 
Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at: http://www.
drugsincontext.com/wp-content/uploads/2018/01/dic.212520-COI.pdf
Funding declaration: No financial support was received.
Copyright: Copyright © 2018 Nakasone ES, Hurvitz SA, McCann KE. Published by Drugs in Context under Creative Commons License Deed CC 
BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. 
No commercial use without permission.
Correct attribution: Copyright © 2018 Nakasone ES, Hurvitz SA, McCann KE. https://doi.org/10.7573/dic.212520. Published by Drugs in 
Context under Creative Commons License Deed CC BY NC ND 4.0.
Article URL: http://www.drugsincontext.com/harnessing-the-immune-system-in-the-battle-against-breast-cancer
Correspondence: Kelly E McCann, Division of Hematology/Oncology, UCLA Department of Medicine, 2020 Santa Monica Suite 580, Santa 
Monica, CA 90404, USA. kmccann@mednet.ucla.edu
Provenance: invited; externally peer reviewed.
Submitted: 5 December 2017; Peer review comments to author: 9 January 2018; Revised manuscript received: 16 January 2018; 
Accepted: 17 January 2018; Publication date: 12 February 2018.
Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.
BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252772009. 
For all manuscript and submissions enquiries, contact the Editorial office dic.editorial@bioexcelpublishing.com 
For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com
Nakasone ES, Hurvitz SA, McCann KE. Drugs in Context 2018; 7: 212520. DOI: 10.7573/dic.212520 12 of 21
ISSN: 1740-4398
REVIEW – Harnessing the immune system in the battle against breast cancer drugsincontext.com
5. Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E. ESMO Guidelines Working Group. Locally recurrent or metastatic 
breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23:vii11–vii19.  
http://dx.doi.org/10.1093/annonc/mds232
6. Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell. 
2010;18:884–901. http://dx.doi.org/10.1016/j.devcel.2010.05.012
7. Place AE, Jin Huh S, Polyak K. The microenvironment in breast cancer progression: biology and implications for treatment. Breast 
Cancer Res. 2011;13:277. http://dx.doi.org/10.1186/bcr2912
8. Spaw M, Anant S, Thomas SM. Stromal contributions to the carcinogenic process. Mol Carcinog. 2017;56:1199–213.  
http://dx.doi.org/10.1002/mc.22583
9. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001;411:375–9.  
http://dx.doi.org/10.1038/35077241
10. Yuan Y, Jiang Y-C, Sun C-K, Chen Q-M. Role of the tumor microenvironment in tumor progression and the clinical applications 
(review). Oncol Rep. 2016;35:2499–515. http://dx.doi.org/10.3892/or.2016.4660
11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.  
http://dx.doi.org/10.1016/j.cell.2011.02.013
12. Virchow RLK. Cellular Pathology as Based Upon Physiological and Pathological Histology. Translated from the 2d Edition of the 
original by Frank Chance. With notes and numerous emendations, principally from MS. Notes of the author. Philadelphia, USA:  
JB Lippincott 1863. http://dx.doi.org/10.5962/bhl.title.32770
13. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 
1986;315:1650–59. http://dx.doi.org/10.1056/NEJM198612253152606
14. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 
2012;21:309–22. http://dx.doi.org/10.1016/j.ccr.2012.02.022
15. Dvorak HF. Tumors: wounds that do not heal – redux. Cancer Immunol Res. 2015;3:1–11.  
http://dx.doi.org/10.1158/2326-6066.CIR-14-0209
16. Moore OS, Foote FW. The relatively favorable prognosis of medullary carcinoma of the breast. Cancer. 1949;2:635–42.
17. Berg JW. Inflammation and prognosis in breast cancer; a search for host resistance. Cancer. 1959;12:714–20.
18. Tanaka H, Shimoda T, Uchida K, Suzuki T, Ischikawa E. Immunohistochemical study on the distribution and significance of 
mononuclear cells in human breast carcinoma. Acta Pathol Jpn. 1986;36:1455–68.
19. Bhan AK, DesMarais CL. Immunohistologic characterization of major histocompatibility antigens and inflammatory cellular 
infiltrate in human breast cancer. J Natl Cancer Inst. 1983;71:507–16.
20. Gil Del Alcazar CR, Huh SJ, Ekram MB, Trinh A, Liu LL, Beca F, Zi X, Kwak M, Bergholtz H, Su Y, Ding L, Russnes HG, Richardson AL, 
Babski K, Min Hui Kim E, McDonnell CH 3rd, Wagner J, Rowberry R, Freeman GJ, Dillon D, Sorlie T, Coussens LM, Garber JE, Fan R, 
Bobolis K, Allred DC, Jeong J, Park SY, Michor F, Polyak K. Immune escape in breast cancer during in situ to invasive carcinoma 
transition. Cancer Discov. 2017;7:1098–115. http://dx.doi.org/10.1158/2159-8290.CD-17-0222
21. DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and 
innate immune cells during breast cancer progression. Breast Cancer Res. 2007;9:539. http://dx.doi.org/10.1186/bcr1746
22. Ogiya R, Niikura N, Kumaki N, Bianchini G, Kitano S, Iwamoto T, Hayashi N, Yokoyama K, Oshitanai R, Terao M, Morioka T, Tsuda B, 
Okamura T, Saito Y, Suzuki Y, Tokuda Y. Comparison of tumor‐infiltrating lymphocytes between primary and metastatic tumors 
in breast cancer patients. Cancer Sci. 2016;107:1730–5. http://dx.doi.org/10.1111/cas.13101
23. Leong PP, Mohammad R, Ibrahim N, Ithnin H, Abdullah M, Davis WC, Seow HF. Phenotyping of lymphocytes expressing 
regulatory and effector markers in infiltrating ductal carcinoma of the breast. Immunol Lett. 2006;102:229–36.  
http://dx.doi.org/10.1016/j.imlet.2005.09.006
24. Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, Chauffert B, Fumoleau P, Ghiringhelli F. Pathologic complete response to 
neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory  
T cells. Clin Cancer Res. 2008;14:2413–20. http://dx.doi.org/10.1158/1078-0432.CCR-07-4491
25. Chen Z, Chen X, Zhou E, Chen G, Qian K, Wu X, Miao X, Tang Z. Intratumoral CD8+ cytotoxic lymphocyte is a favorable prognostic 
marker in node-negative breast cancer. Plos One. 2014;9:e95475. http://dx.doi.org/10.1371/journal.pone.0095475
26. Xu Y, Lan S, Zheng Q. Prognostic significance of infiltrating immune cell subtypes in invasive ductal carcinoma of the breast. 
Tumori. 2017;0. https://doi.org/10.5301/tj.5000624
27. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR. Tumor-infiltrating CD8+ lymphocytes 
predict clinical outcome in breast cancer. J Clin Oncol. 2011;29:1949–55. http://dx.doi.org/10.1200/JCO.2010.30.5037
28. Verma C, Kaewkangsadan V, Eremin JM, Cowley GP, Ilyas M, El-Sheemy MA, Eremin O. Natural killer (NK) cell profiles in blood 
and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete 
response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and 
surgery. J Transl Med. 2015;13:180. http://dx.doi.org/10.1186/s12967-015-0535-8
Nakasone ES, Hurvitz SA, McCann KE. Drugs in Context 2018; 7: 212520. DOI: 10.7573/dic.212520 13 of 21
ISSN: 1740-4398
REVIEW – Harnessing the immune system in the battle against breast cancer drugsincontext.com
29. Mandal A, Viswanathan C. Natural killer cells: in health and disease. Hematol Oncol Stem Cell Ther. 2015;8:47–55.  
http://dx.doi.org/10.1016/j.hemonc.2014.11.006
30. Tu MM, Mahmoud AB, Wight A, Mottashed A, Bélanger S, Rahim MM, Abou-Samra E, Makrigiannis AP. Ly49 family receptors  
are required for cancer immunosurveillance mediated by natural killer cells. Cancer Res. 2014;74:3684–94.  
http://dx.doi.org/10.1158/0008-5472.CAN-13-3021
31. Tu MM, Rahim MMA, Sayed C, Mahmoud AB, Makrigiannis AP. Immunosurveillance and immunoediting of breast cancer via class 
I MHC receptors. Cancer Immunol Res. 2017;5(11):1016–28. http://dx.doi.org/10.1158/2326-6066.CIR-17-0056
32. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 
2010;10:490–500. http://dx.doi.org/10.1038/nri2785
33. Yamaguchi T, Wing JB, Sakaguchi S. Two modes of immune suppression by Foxp3(+) regulatory T cells under inflammatory or 
non-inflammatory conditions. Semin Immunol. 2011;23:424–30. http://dx.doi.org/10.1016/j.smim.2011.10.002
34. Xu L, Xu W, Qiu S, Xiong S. Enrichment of CCR6+Foxp3+ regulatory T cells in the tumor mass correlates with impaired  
CD8+ T cell function and poor prognosis of breast cancer. Clin Immunol. 2010;135:466–75.  
http://dx.doi.org/10.1016/j.clim.2010.01.014
35. Watanabe MAE, Oda JMM, Amarante MK, Cesar Voltarelli J. Regulatory T cells and breast cancer: implications for 
immunopathogenesis. Cancer Metastasis Rev. 2010;29:569–79. http://dx.doi.org/10.1007/s10555-010-9247-y
36. Knutson KL, Dang Y, Lu H, Lukas J, Almand B, Gad E, Azeke E, Disis ML. IL-2 immunotoxin therapy modulates tumor-associated 
regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol. 
2006;177:84–91. https://dx.doi.org/10.4049/jimmunol.177.1.84
37. Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell DJ Jr, Colligon TA, Trosko JA, Leinbach LI, Pletcher CH, Tweed CK, 
DeMichele A, Fox KR, Domchek SM, Riley JL, Vonderheide RH. CD25 blockade depletes and selectively reprograms regulatory 
T cells in concert with immunotherapy in cancer patients. Sci Transl Med. 2012;4:134ra62.  
http://dx.doi.org/10.1126/scitranslmed.3003330
38. Oldford SA, Robb JD, Codner D, Gadag V, Watson PH, Drover S. Tumor cell expression of HLA-DM associates with a Th1 profile 
and predicts improved survival in breast carcinoma patients. Int Immunol. 2006;18:1591–602.  
http://dx.doi.org/10.1093/intimm/dxl092
39. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM. CD4(+) T cells regulate pulmonary metastasis 
of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009;16:91–102.  
http://dx.doi.org/10.1016/j.ccr.2009.06.018
40. Zhang Q, Qin J, Zhong L, Gong L, Zhang B, Zhang Y, Gao WQ. CCL5-Mediated Th2 immune polarization promotes metastasis in 
luminal breast cancer. Cancer Res. 2015;75:4312–21. http://dx.doi.org/10.1158/0008-5472.CAN-14-3590
41. Yang L, Qi Y, Hu J, Tang L, Zhao S, Shan B. Expression of Th17 cells in breast cancer tissue and its association with clinical 
parameters. Cell Biochem Biophys. 2012;62:153–9. http://dx.doi.org/10.1007/s12013-011-9276-3
42. Zhu X, Mulcahy LA, Mohammed RA, Lee AH, Franks HA, Kilpatrick L, Yilmazer A, Paish EC, Ellis IO, Patel PM, Jackson AM. IL-17 
expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res. 
2008;10:R95. http://dx.doi.org/10.1186/bcr2195
43. Cochaud S, Giustiniani J, Thomas C, Laprevotte E, Garbar C, Savoye AM, Curé H, Mascaux C, Alberici G, Bonnefoy N, Eliaou JF, 
Bensussan A, Bastid J. IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2. 
Sci Rep. 2013;3:3456. http://dx.doi.org/10.1038/srep03456
44. O’Sullivan C, Lewis CE. Tumour-associated leucocytes: friends or foes in breast carcinoma. J Pathol. 1994;172:229–35.  
http://dx.doi.org/10.1002/path.1711720302
45. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN, Pollard JW. Macrophages regulate the angiogenic switch in 
a mouse model of breast cancer. Cancer Res. 2006;66:11238–46. http://dx.doi.org/10.1158/0008-5472.CAN-06-1278
46. Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, Segall JE, Pollard JW, Condeelis J. Direct visualization of macrophage-
assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007;67:2649–56.  
http://dx.doi.org/10.1158/0008-5472.CAN-06-1823
47. Ahn GO, Tseng D, Liao CH, Dorie MJ, Czechowicz A, Brown JM. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to 
radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci USA. 2010;107:8363–8.  
http://dx.doi.org/10.1073/pnas.0911378107
48. Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K, Bell-McGuinn KM, Zabor EC, Brogi E, Joyce JA. Macrophages and 
cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 2011;25:2465–79.  
http://dx.doi.org/10.1101/gad.180331.111
49. Nakasone ES, Askautrud HA, Kees T, Park JH, Plaks V, Ewald AJ, Fein M, Rasch MG, Tan YX, Qiu J, Park J, Sinha P, Bissell MJ, Frengen E, 
Werb Z, Egeblad M. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to 
resistance. Cancer Cell. 2012;21:488–503. http://dx.doi.org/10.1016/j.ccr.2012.02.017
Nakasone ES, Hurvitz SA, McCann KE. Drugs in Context 2018; 7: 212520. DOI: 10.7573/dic.212520 14 of 21
ISSN: 1740-4398
REVIEW – Harnessing the immune system in the battle against breast cancer drugsincontext.com
50. Medrek C, Pontén F, Jirström K, Leandersson K. The presence of tumor associated macrophages in tumor stroma as a prognostic 
marker for breast cancer patients. BMC Cancer. 2012;12:306. http://dx.doi.org/10.1186/1471-2407-12-306
51. Klingen TA, Chen Y, Aas H, Wik E, Akslen LA. Tumor associated macrophages are strongly related to vascular invasion, non-
luminal subtypes and interval breast cancer. Hum Pathol. 2017;69:72–80. http://dx.doi.org/10.1016/j.humpath.2017.09.001
52. Kankkunen JP, Harvima IT, Naukkarinen A. Quantitative analysis of tryptase and chymase containing mast cells in benign and 
malignant breast lesions. Int J Cancer. 1997;72:385–8.
53. Cimpean AM, Tamma R, Ruggieri S, Nico B, Toma A, Ribatti D. Mast cells in breast cancer angiogenesis. Crit Rev Oncol Hematol. 
2017;115:23–26. http://dx.doi.org/10.1016/j.critrevonc.2017.04.009
54. Markowitz J, Wesolowski R, Papenfuss T, Brooks TR, Carson WE 3rd. Myeloid-derived suppressor cells in breast cancer. Breast 
Cancer Res Treat. 2013;140:13–21. http://dx.doi.org/10.1007/s10549-013-2618-7
55. Hansen MH, Nielsen H, Ditzel HJ. The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed 
against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci USA. 2001;98:12659–64. 
http://dx.doi.org/10.1073/pnas.171460798
56. Coronella JA, Spier C, Welch M, Trevor KT, Stopeck AT, Villar H, Hersh EM. Antigen-driven oligoclonal expansion of tumor-
infiltrating B cells in infiltrating ductal carcinoma of the breast. J Immunol. 2002;169:1829–36.  
https://dx.doi.org/10.4049/jimmunol.169.4.1829
57. Nzula S, Going JJ, Stott DI. Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes 
infiltrating human ductal breast carcinomas. Cancer Res. 2003;63:3275–80.
58. Simsa P, Teillaud J-L, Stott DI, Toth J, Kotlan B. Tumor-infiltrating B cell immunoglobulin variable region gene usage in invasive 
ductal breast carcinoma. Pathol Oncol Res. 2005;11:92–97.
59. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, 
Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, 
Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L,  
Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL,  
Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, 
Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, 
Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, 
Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, 
Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, 
Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML. Defining the critical hurdles in cancer immunotherapy. J Transl 
Med. 2011;9:214. http://dx.doi.org/10.1186/1479-5876-9-214
60. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev 
Immunol. 2006;6:715–27. http://dx.doi.org/10.1038/nri1936
61. Wright SE. Immunotherapy of breast cancer. Expert Opin Biol Ther. 2012;12:479–90. http://dx.doi.org/10.1517/14712598.2012.665445
62. Morrissey KM, Yuraszeck TM, Li CC, Zhang Y, Kasichayanula S. Immunotherapy and novel combinations in oncology: current 
landscape, challenges, and opportunities. Clin Transl Sci. 2016;9:89–104. http://dx.doi.org/10.1111/cts.12391
63. Li C-Y, Huang Q, Kung H-F. Cytokine and immuno-gene therapy for solid tumors. Cell Mol Immunol. 2005;2:81–91.
64. Kim-Schulze S, Taback B, Kaufman HL. Cytokine therapy for cancer. Surg Oncol Clin N Am. 2007;16:793–818, viii.  
http://dx.doi.org/10.1016/j.soc.2007.07.011
65. Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers (Basel). 2011;3:3856–93.  
http://dx.doi.org/10.3390/cancers3043856
66. Yao M, Brummer G, Acevedo D, Cheng N. Cytokine regulation of metastasis and tumorigenicity. Adv Cancer Res.  
2016;132:265–367. http://dx.doi.org/10.1016/bs.acr.2016.05.005
67. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. 
Clin Orthop Relat Res. 1991;262:3–11.
68. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment 
of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 
1994;271:907–13. http://dx.doi.org/10.1001/jama.1994.03510360033032
69. Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192:5451–8.  
http://dx.doi.org/10.4049/jimmunol.1490019
70. Gutterman JU, Blumenschein GR, Alexanian R, Yap HY, Buzdar AU, Cabanillas F, Hortobagyi GN, Hersh EM, Rasmussen SL,  
Harmon M, Kramer M, Pestka S. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple 
myeloma, and malignant lymphoma. Ann Intern Med. 1980;93:399–406. http://dx.doi.org/10.7326/0003-4819-93-3-399
71. Borden EC, Holland JF, Dao TL, Gutterman JU, Wiener L, Chang Y-C, Patel J. Leukocyte-derived interferon (alpha) in human breast 
carcinoma. The American Cancer Society phase II trial. Ann Intern Med. 1982;97:1–6. http://dx.doi.org/10.7326/0003-4819-97-1-1
Nakasone ES, Hurvitz SA, McCann KE. Drugs in Context 2018; 7: 212520. DOI: 10.7573/dic.212520 15 of 21
ISSN: 1740-4398
REVIEW – Harnessing the immune system in the battle against breast cancer drugsincontext.com
72. Sherwin SA, Mayer D, Ochs JJ, Abrams PG, Knost JA, Foon KA, Fein S, Oldham RK. Recombinant leukocyte A interferon in 
advanced breast cancer. Results of a phase II efficacy trial. Ann Intern Med. 1983;98:598–602.
73. Quesada JR, Hawkins M, Horning S, Alexanian R, Borden E, Merigan T, Adams F, Gutterman JU. Collaborative phase I-II study 
of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple 
myeloma. Am J Med. 1984;77:427–32. https://dx.doi.org/10.1016/0002-9343(84)90097-4
74. Barreras L, Vogel CL, Koch G, Marcus SG. Phase II trial of recombinant beta (IFN-betaser) interferon in the treatment of metastatic 
breast cancer. Invest New Drugs. 1988;6:211–5.
75. Bruntsch U, Groos G, Tigges FJ, Hofschneider H, Gallmeier WM. Lack of response in nine patients with breast cancer treated with 
fibroblast interferon. Cancer Chemother Pharmacol. 1984;13:39–42.
76. Muss HB, Caponera M, Zekan PJ, Jackson DV Jr, Stuart JJ, Richards F, Cooper MR, Levin EA, Reich SD, Capizzi RL. Recombinant 
gamma interferon in advanced breast cancer: a phase II trial. Invest New Drugs. 1986;4:377–81.
77. Kimmick G, Ratain MJ, Berry D, Woolf S, Norton L, Muss HB. Cancer and Leukemia Group B. Subcutaneously administered 
recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and 
Leukemia Group B (CALGB 9041). Invest New Drugs. 2004;22:83–89.
78. Sabel MS, Skitzki J, Stoolman L, Egilmez NK, Mathiowitz E, Bailey N, Chang WJ, Chang AE. Intratumoral IL-12 and TNF-alpha-
loaded microspheres lead to regression of breast cancer and systemic antitumor immunity. Ann Surg Oncol. 2004;11:147–56. 
http://dx.doi.org/10.1245/ASO.2004.03.022
79. Repka T, Chiorean EG, Gay J, Herwig KE, Kohl VK, Yee D, Miller JS. Trastuzumab and interleukin-2 in HER2-positive 
metastatic breast cancer: a pilot study. Clin Cancer Res. 2003;9:2440–6.  
http://clincancerres.aacrjournals.org/content/9/7/2440.long
80. Bekaii-Saab TS, Roda JM, Guenterberg KD, Ramaswamy B, Young DC, Ferketich AK, Lamb TA, Grever MR, Shapiro CL, Carson 
WE 3rd. A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing 
malignancies. Mol Cancer Ther. 2009;8:2983–91. http://dx.doi.org/10.1158/1535-7163.MCT-09-0820
81. Stewart AK, Lassam NJ, Quirt IC, Bailey DJ, Rotstein LE, Krajden M, Dessureault S, Gallinger S, Cappe D, Wan Y, Addison CL, Moen 
RC, Gauldie J, Graham FL. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: 
results of a phase 1 clinical trial. Gene Ther. 1999;6:350–63. http://dx.doi.org/10.1038/sj.gt.3300833
82. Chaurasiya S, Hew P, Crosley P, Sharon D, Potts K, Agopsowicz K, Long M, Shi C, Hitt MM. Breast cancer gene therapy using 
an adenovirus encoding human IL-2 under control of mammaglobin promoter/enhancer sequences. Cancer Gene Ther. 
2016;23:178–87. http://dx.doi.org/10.1038/cgt.2016.18
83. Yousefi F, Siadat SD, Saraji AA, Hesaraki S, Aslani MM, Mousavi SF, Imani Fooladi AA. Tagging staphylococcal enterotoxin B (SEB) 
with TGFaL3 for breast cancer therapy. Tumour Biol. 2016;37:5305–16. http://dx.doi.org/10.1007/s13277-015-4334-x
84. Valedkarimi Z, Nasiri H, Aghebati-Maleki L, Majidi J. Antibody-cytokine fusion proteins for improving efficacy and safety of 
cancer therapy. Biomed Pharmacother. 2017;95:731–42. http://dx.doi.org/10.1016/j.biopha.2017.07.160
85. Wingard JR, Elmongy M. Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or 
antibiotics. Crit Rev Oncol Hematol. 2009;72:144–54. http://dx.doi.org/10.1016/j.critrevonc.2009.01.003
86. Crawford J, Allen J, Armitage J, Blayney DW, Cataland SR, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, 
Steensma DP, Vadhan-Raj S, Westervelt P, Westmoreland M. National Comprehensive Cancer Network. Myeloid growth factors. J 
Natl Compr Canc Netw. 2011;9:914–32. http://dx.doi.org/10.6004/jnccn.2011.0075
87. Palucka AK, Coussens LM. The basis of oncoimmunology. Cell. 2016;164:1233–47. http://dx.doi.org/10.1016/j.cell.2016.01.049
88. Adams S. Toll-like receptor agonists in cancer therapy. Immunotherapy. 2009;1:949–64. http://dx.doi.org/10.2217/imt.09.70
89. Braun W, Plescia OJ, Raskova J, Webb D. Basic proteins and synthetic polynucleotides as modifiers of immunogenicity of 
syngeneic tumor cells. Isr J Med Sci. 1971;7:72–82.
90. Lacour F, Spira A, Lacour J, Prade M. Polyadenylic-polyuridylic acid, an adjunct to surgery in the treatment of spontaneous 
mammary tumors in C3H-He mice and transplantable melanoma in the hamster. Cancer Res. 1972;32:648–9. 
http://cancerres.aacrjournals.org/content/canres/32/3/648.full.pdf
91. Lacour F, Delage G, Chianale C. Reduced incidence of spontaneous mammary tumors in C3H/He mice after treatment with 
polyadenylate-polyuridylate. Science. 1975;187:256–7.
92. Lacour J, Lacour F, Spira A, Michelson M, Petit JY, Delage G, Sarrazin D, Contesso G, Viguier J. Adjuvant treatment with 
polyadenylic-polyuridylic acid (Polya.Polyu) in operable breast cancer. Lancet. 1980;2:161–4. 
https://dx.doi.org/10.1016/S0140-6736(80)90057-4
93. Lacour J, Lacour F, Spira A, Michelson M, Petit JY, Delage G, Sarrazin D, Contesso G, Viguier J. Adjuvant treatment with 
polyadenylic-polyuridylic acid in operable breast cancer: updated results of a randomised trial. Br Med J (Clin Res Ed). 
1984;288:589–92.
94. Lacour J, Lacour F, Ducot B, Spira A, Michelson M, Petit JY, Sarrazin D, Contesso G. Polyadenylic-polyuridylic acid as adjuvant in 
the treatment of operable breast cancer: recent results. Eur J Surg Oncol. 1988;14:311–6.
Nakasone ES, Hurvitz SA, McCann KE. Drugs in Context 2018; 7: 212520. DOI: 10.7573/dic.212520 16 of 21
ISSN: 1740-4398
REVIEW – Harnessing the immune system in the battle against breast cancer drugsincontext.com
95. Lacour J, Laplanche A, Delozier T, Berlie J, Mourali N, Julien JP, De Gislain C, Namer M, Petit JC, Denis V. Polyadenylic-polyuridylic 
acid plus locoregional and pelvic radiotherapy versus chemotherapy with CMF as adjuvants in operable breast cancer. A 6 
1/2 year follow-up analysis of a randomized trial of the French Federation of Cancer Centers (F.F.C.C.). Breast Cancer Res Treat. 
1991;19:15–21.
96. Laplanche A, Alzieu L, Delozier T, Berlie J, Veyret C, Fargeot P, Luboinski M, Lacour J. Polyadenylic-polyuridylic acid plus 
locoregional radiotherapy versus chemotherapy with CMF in operable breast cancer: a 14 year follow-up analysis of a 
randomized trial of the Fédération Nationale des Centres de Lutte contre le Cancer (FNCLCC). Breast Cancer Res Treat. 
2000;64:189–91.
97. Potmesil M, Goldfeder A. Inhibitory effect of polyinosinic:polycytidylic acid on the growth of transplantable mouse mammary 
carcinoma. Proc Soc Exp Biol Med. 1972;139:1392–7.
98. Lee AE, Rogers LA, Longcroft JM, Jeffery RE. Reduction of metastasis in a murine mammary tumour model by heparin and 
polyinosinic-polycytidylic acid. Clin Exp Metastasis. 1990;8:165–71. http://dx.doi.org/10.1007/BF00117789
99. Charlebois R, Bertrand A, Allard D, Buisseret L, Turcotte M, Pommey S, Chrobak P, Stagg J. PolyI:C and CpG synergize with anti-
ErbB2 mAb for treatment of breast tumors resistant to immune checkpoint inhibitors. Cancer Res. 2017;77:312–9.  
http://dx.doi.org/10.1158/0008-5472.CAN-16-1873
100. Curigliano G, Romieu G, Campone M, Dorval T, Duck L, Canon JL, Roemer-Becuwe C, Roselli M, Neciosup S, Burny W, Callegaro A, 
de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF. A phase I/II trial of the safety and clinical activity of a HER2-protein based 
immunotherapeutic for treating women with HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2016;156:301–10. 
http://dx.doi.org/10.1007/s10549-016-3750-y
101. Li L, Wang W, Pan H, Ma G, Shi X, Xie H, Liu X, Ding Q, Zhou W, Wang S. Microwave ablation combined with OK-432 induces 
Th1-type response and specific antitumor immunity in a murine model of breast cancer. J Transl Med. 2017;15:23.  
http://dx.doi.org/10.1186/s12967-017-1124-9
102. Adams S, Kozhaya L, Martiniuk F, Meng TC, Chiriboga L, Liebes L, Hochman T, Shuman N, Axelrod D, Speyer J, Novik Y, Tiersten A, 
Goldberg JD, Formenti SC, Bhardwaj N, Unutmaz D, Demaria S. Topical TLR7 agonist imiquimod can induce immune-mediated 
rejection of skin metastases in patients with breast cancer. Clin Cancer Res. 2012;18:6748–57.  
http://dx.doi.org/10.1158/1078-0432.CCR-12-1149
103. Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ. Evidence for a tumoral immune 
resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9:1269–74.  
http://dx.doi.org/10.1038/nm934
104. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an 
immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005;11:312–9.  
http://dx.doi.org/10.1038/nm1196
105. Soliman HH, Jackson E, Neuger T, Dees EC, Harvey RD, Han H, Ismail-Khan R, Minton S, Vahanian NN, Link C, Sullivan DM, Antonia S. 
A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid 
tumors. Oncotarget. 2014;5:8136–46. http://dx.doi.org/10.18632/oncotarget.2357
106. Soliman HH, Minton SE, Han HS, Ismail-Khan R, Neuger A, Khambati F, Noyes D, Lush R, Chiappori AA, Roberts JD, Link C, 
Vahanian NN, Mautino M, Streicher H, Sullivan DM, Antonia SJ. A phase I study of indoximod in patients with advanced 
malignancies. Oncotarget. 2016;7:22928–38. http://dx.doi.org/10.18632/oncotarget.8216
107. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4:71–8.  
http://dx.doi.org/10.1038/nrc1256
108. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and 
prognosis in invasive breast carcinoma. Cancer Res. 1996;56:4625–9. http://cancerres.aacrjournals.org/content/56/20/4625.long
109. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, 
Hwang ES, Jirström K, West BL, Coussens LM. Leukocyte complexity predicts breast cancer survival and functionally regulates 
response to chemotherapy. Cancer Discov. 2011;1:54–67. http://dx.doi.org/10.1158/2159-8274.CD-10-0028
110. Chitu V, Stanley ER. Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol. 2006;18:39–48.  
http://dx.doi.org/10.1016/j.coi.2005.11.006
111. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, Jones T, Jucknischke U, 
Scheiblich S, Kaluza K, Gorr IH, Walz A, Abiraj K, Cassier PA, Sica A, Gomez-Roca C, de Visser KE, Italiano A, Le Tourneau C,  
Delord JP, Levitsky H, Blay JY, Rüttinger D. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a  
strategy for cancer therapy. Cancer Cell. 2014;25:846–59. http://dx.doi.org/10.1016/j.ccr.2014.05.016
112. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW. CCL2 recruits inflammatory monocytes 
to facilitate breast-tumour metastasis. Nature. 2011;475:222–5. http://dx.doi.org/10.1038/nature10138
113. Bonapace L, Coissieux MM, Wyckoff J, Mertz KD, Varga Z, Junt T, Bentires-Alj M. Cessation of CCL2 inhibition accelerates breast 
cancer metastasis by promoting angiogenesis. Nature. 2014;515:130–3. http://dx.doi.org/10.1038/nature13862
Nakasone ES, Hurvitz SA, McCann KE. Drugs in Context 2018; 7: 212520. DOI: 10.7573/dic.212520 17 of 21
ISSN: 1740-4398
REVIEW – Harnessing the immune system in the battle against breast cancer drugsincontext.com
114. Sandhu SK, Papadopoulos K, Fong PC, Patnaik A, Messiou C, Olmos D, Wang G, Tromp BJ, Puchalski TA, Balkwill F, Berns B, 
Seetharam S, de Bono JS, Tolcher AW. A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal 
antibody against CC-chemokine ligand 2 in patients with solid tumors. Cancer Chemother Pharmacol. 2013;71:1041–50.  
http://dx.doi.org/10.1007/s00280-013-2099-8
115. Pienta KJ, Machiels JP, Schrijvers D, Alekseev B, Shkolnik M, Crabb SJ, Li S, Seetharam S, Puchalski TA, Takimoto C, Elsayed Y, 
Dawkins F, de Bono JS. Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 
(CCL2), in metastatic castration-resistant prostate cancer. Invest New Drugs. 2013;31:760–8.  
http://dx.doi.org/10.1007/s10637-012-9869-8
116. Vela M, Aris M, Llorente M, Garcia-Sanz JA, Kremer L. Chemokine receptor-specific antibodies in cancer immunotherapy: 
achievements and challenges. Front Immunol. 2015;6:12. http://dx.doi.org/10.3389/fimmu.2015.00012
117. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. 
Cell. 2015;161:205–14. http://dx.doi.org/10.1016/j.cell.2015.03.030
118. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.  
http://dx.doi.org/10.1038/nrc3239
119. Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 
2016;39:98–106. http://dx.doi.org/10.1097/COC.0000000000000239
120. Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, Holt RA. Neo-antigens predicted by tumor genome meta-
analysis correlate with increased patient survival. Genome Res. 2014;24:743–50. http://dx.doi.org/10.1101/gr.165985.113
121. Denkert C, von Minckwitz G, Darb-Esfahani S, Ingold Heppner B, Klauschen F, Furlanetto J, Pfitzner B, Huober J, Schmitt W, 
Blohmer J-U, Kümmel S, Engels K, Lederer B, Schneeweiss A, Hartmann A, Jakisch C, Untch M, Hanusch C, Weber K, Loibl S. 
Abstract S1-09: evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes 
of breast cancer treated with neoadjuvant therapy – a metaanalysis of 3771 patients. Cancer Res. 2017;77:S1–09.  
http://dx.doi.org/10.1158/1538-7445.SABCS16-S1-09
122. Ali HR, Glont SE, Blows FM, Provenzano E, Dawson SJ, Liu B, Hiller L, Dunn J, Poole CJ, Bowden S, Earl HM, Pharoah PD, Caldas C. 
PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. 
Ann Oncol. 2015;26:1488–93. http://dx.doi.org/10.1093/annonc/mdv192
123. Sabatier R, Finetti P, Mamessier E, Raynaud S, Cervera N, Lambaudie E, Jacquemier J, Viens P, Birnbaum D, Bertucci F. Prognostic 
and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015;6:5449–64.  
http://dx.doi.org/10.18632/oncotarget.3216
124. Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, Karantza V, Buisseret L.  
Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 
2016;34:2460–7. http://dx.doi.org/10.1200/JCO.2015.64.8931
125. Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, 
Toppmeyer, O'Shaughnessy J, Loi S, Paluch-Shimon S, Card D, Zhao J, Karantza V, Cortes J. Phase 2 study of pembrolizumab 
(pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. JCO. 
2017;35:1008. http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.1088
126. Rugo HS, Delord J-P, Im S-A, Ott PA, Piha-Paul SA, Bedard PL, Sachdev J, Le Tourneau C, van Brummelen E, Varga A, Saraf S, 
Pietrangelo D, Karantza V, Tan A. Abstract S5-07: preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with 
PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028. Cancer Res. 
2016;76:S5–07. http://dx.doi.org/10.1158/1538-7445.SABCS15-S5-07
127. Adams S, Diamond JR, Hamilton EP, Pohlmann PR, Tolaney SM, Molinero L. Phase Ib trial of atezolizumab in combination with 
nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). JCO. 2016;34:1009.  
http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.1009
128. Emens LA, Adams S, Loi S, Schneeweiss A, Rugo HS, Winer EP. IMpassion130: a Phase III randomized trial of atezolizumab with 
nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC). JCO. 2016;34:TPS1104.  
http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.TPS1104#affiliationsContainer
129. Dirix LY, Takacs I, Nikolinakos P, Jerusalem G, Arkenau H-T, Hamilton EP P, von Heydebreck A, Grote H-J, Chin K, Lippman ME. 
Abstract S1-04: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: 
a phase Ib JAVELIN solid tumor trial. Cancer Res. 2016;76:S1–04. http://dx.doi.org/10.1158/1538-7445.SABCS15-S1-04
130. Nanda R, Liu MC, Yau C, Asare S, Hylton N, Van't Veer L. Pembrolizumab plus standard neoadjuvant therapy for  
high-risk breast cancer (BC): results from I-SPY 2. JCO. 2017;35:506.  
http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.506#affiliationsContainer
131. Schmid P, Cruz C, Braiteh FS, Eder JP, Tolaney S, Kuter I, Nanda R, Chung C, Cassier P, Delord J-P, Gordon M, Li Y, Liu B, O'Hear C,  
Faso M, Molinero L, Emens L. Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): long-term clinical outcomes and 
biomarker analyses. Cancer Res. 2017;77:2986. http://dx.doi.org/10.1158/1538-7445.AM2017-2986
Nakasone ES, Hurvitz SA, McCann KE. Drugs in Context 2018; 7: 212520. DOI: 10.7573/dic.212520 18 of 21
ISSN: 1740-4398
REVIEW – Harnessing the immune system in the battle against breast cancer drugsincontext.com
132. Safonov A, Jiang T, Bianchini G, Győrffy B, Karn T, Hatzis C, Pusztai L. Abstract S1-07: Immune sculpting of the triple negative 
breast cancer genome. Cancer Res. 2017;77:S1–07.
133. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, Tangsombatvisit 
S, Grosso JF, Netto G, Smeltzer MP, Chaux A, Utz PJ, Workman CJ, Pardoll DM, Korman AJ, Drake CG, Vignali DA. Immune 
inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 
2012;72:917–27. http://dx.doi.org/10.1158/0008-5472.CAN-11-1620
134. Das M, Zhu C, Kuchroo VK. Tim-3 and its role in regulating anti-tumor immunity. Immunol Rev. 2017;276:97–111.  
http://dx.doi.org/10.1111/imr.12520
135. Piconese S, Valzasina B, Colombo MP. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection.  
J Exp Med. 2008;205:825–39. http://dx.doi.org/10.1084/jem.20071341
136. Moreno Ayala MA, Gottardo MF, Asad AS, Zuccato C, Nicola A, Seilicovich A, Candolfi M. Immunotherapy for the treatment of 
breast cancer. Expert Opin Biol Ther. 2017;17:797–812. http://dx.doi.org/10.1080/14712598.2017.1324566
137. Choi BD, Cai M, Bigner DD, Mehta AI, Kuan CT, Sampson JH. Bispecific antibodies engage T cells for antitumor immunotherapy. 
Expert Opin Biol Ther. 2011;11:843–53. http://dx.doi.org/10.1517/14712598.2011.572874
138. Weiner LM, Clark JI, Ring DB, Alpaugh RK. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting 
c-erbB-2 and Fc gamma RIII. J Hematother. 1995;4:453–6. http://dx.doi.org/10.1089/scd.1.1995.4.453
139. Sen M, Wankowski DM, Garlie NK, Siebenlist RE, Van Epps D, LeFever AV, Lum LG. Use of anti-CD3 x anti-HER2/neu bispecific 
antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors. J Hematother Stem Cell Res. 2001;10:247–60. 
http://dx.doi.org/10.1089/15258160151134944
140. Flieger D, Kufer P, Beier I, Sauerbruch T, Schmidt-Wolf IG. A bispecific single-chain antibody directed against EpCAM/CD3 in 
combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T 
lymphocytes to EpCAM-expressing tumor cells. Cancer Immunol Immunother. 2000;49:441–8.
141. Amann M, D'Argouges S, Lorenczewski G, Brischwein K, Kischel R, Lutterbuese R, Mangold S, Rau D, Volkland J, Pflanz S, Raum 
T, Münz M, Kufer P, Schlereth B, Baeuerle PA, Friedrich M. Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during 
long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release. J Immunother. 2009;32:452–64.  
http://dx.doi.org/10.1097/CJI.0b013e3181a1c097
142. Wallace PK, Romet-Lemonne JL, Chokri M, Kasper LH, Fanger MW, Fadul CE. Production of macrophage-activated killer cells 
for targeting of glioblastoma cells with bispecific antibody to FcgammaRI and the epidermal growth factor receptor. Cancer 
Immunol Immunother. 2000;49:493–503.
143. Borghaei H, Alpaugh RK, Bernardo P, Palazzo IE, Dutcher JP, Venkatraj U, Wood WC, Goldstein L, Weiner LM. Induction of adaptive 
Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast 
cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group. J Immunother. 2007;30:455–67.  
http://dx.doi.org/10.1097/CJI.0b013e31803bb421
144. Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Ernstoff MS, Wells W, Barth R, Deo Y, Fisher J, Phipps K, Graziano R, 
Meyer L, Mrozek-Orlowski M, Wardwell K, Guyre V, Morley TL, Arvizu C, Wallace P, Fanger MW. Clinical trials of bispecific antibody 
MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu. J Hematother. 1995;4:471–5.  
http://dx.doi.org/10.1089/scd.1.1995.4.471
145. Pullarkat V, Deo Y, Link J, Spears L, Marty V, Curnow R, Groshen S, Gee C, Weber JS. A phase I study of a HER2/neu bispecific 
antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu. 
Cancer Immunol Immunother. 1999;48:9–21.
146. Fury MG, Lipton A, Smith KM, Winston CB, Pfister DG. A phase-I trial of the epidermal growth factor receptor directed 
bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with 
advanced solid tumors. Cancer Immunol Immunother. 2008;57:155–63. http://dx.doi.org/10.1007/s00262-007-0357-5
147. Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs. 2009;1:539–47.
148. Shalaby MR, Carter P, Maneval D, Giltinan D, Kotts C. Bispecific HER2 x CD3 antibodies enhance T-cell cytotoxicity in vitro and 
localize to HER2-overexpressing xenografts in nude mice. Clin Immunol Immunopathol. 1995;74:185–92.
149. Zhou Y, Gou L-T, Guo Z-H, Liu H-R, Wang J-M, Zhou S-X, Yang J-L, Li X-A. Fully human HER2/cluster of differentiation 3 bispecific 
antibody triggers potent and specific cytotoxicity of T lymphocytes against breast cancer. Mol Med Rep. 2015;12:147–54.  
http://dx.doi.org/10.3892/mmr.2015.3441
150. Lopez-Albaitero A, Xu H, Guo H, Wang L, Wu Z, Tran H, Chandarlapaty S, Scaltriti M, Janjigian Y, de Stanchina E,  
Cheung N-K. Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody. Oncoimmunology. 
2017;6:e1267891. http://dx.doi.org/10.1080/2162402X.2016.1267891
151. Urbanska K, Lynn RC, Stashwick C, Thakur A, Lum LG, Powell DJ Jr. Targeted cancer immunotherapy via combination of designer 
bispecific antibody and novel gene-engineered T cells. J Transl Med. 2014;12:347. http://dx.doi.org/10.1186/s12967-014-0347-2
Nakasone ES, Hurvitz SA, McCann KE. Drugs in Context 2018; 7: 212520. DOI: 10.7573/dic.212520 19 of 21
ISSN: 1740-4398
REVIEW – Harnessing the immune system in the battle against breast cancer drugsincontext.com
152. Grabert RC, Cousens LP, Smith JA, Olson S, Gall J, Young WB, Davol PA, Lum LG. Human T cells armed with Her2/neu bispecific 
antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Clin Cancer Res. 2006;12:569–76.  
http://dx.doi.org/10.1158/1078-0432.CCR-05-2005
153. Jäger M, Schoberth A, Ruf P, Hess J, Lindhofer H. The trifunctional antibody ertumaxomab destroys tumor cells that express low 
levels of human epidermal growth factor receptor 2. Cancer Res. 2009;69:4270–6. http://dx.doi.org/10.1158/0008-5472.CAN-08-2861
154. Kiewe P, Hasmüller S, Kahlert S, Heinrigs M, Rack B, Marmé A, Korfel A, Jäger M, Lindhofer H, Sommer H, Thiel E, Untch M. Phase I 
trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res. 2006;12:3085–
91. http://dx.doi.org/10.1158/1078-0432.CCR-05-2436
155. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 2003;3(8):630–41. http://dx.doi.org/10.1038/nri1150
156. Myc LA, Gamian A, Myc A. Cancer vaccines. Any future? Arch Immunol Ther Exp (Warsz). 2011;59:249–59.  
http://dx.doi.org/10.1007/s00005-011-0129-y
157. Clem AS. Fundamentals of vaccine immunology. J Glob Infect Dis. 2011;3:73–8. http://dx.doi.org/10.4103/0974-777X.77299
158. Sayour EJ, Mitchell DA. Manipulation of innate and adaptive immunity through cancer vaccines. J Immunol Res. 
2017;2017:3145742. http://dx.doi.org/10.1155/2017/3145742
159. Mittendorf EA, Holmes JP, Ponniah S, Peoples GE. The E75 HER2/neu peptide vaccine. Cancer Immunol Immunother. 
2008;57:1511–21. http://dx.doi.org/10.1007/s00262-008-0540-3
160. Mittendorf EA, Clifton GT, Holmes JP, Schneble E, van Echo D, Ponniah S, Peoples GE. Final report of the phase I/II clinical trial of 
the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann 
Oncol. 2014;25:1735–42. http://dx.doi.org/10.1093/annonc/mdu211
161. Wang X, Wang J-P, Maughan MF, Lachman LB. Alphavirus replicon particles containing the gene for HER2/neu inhibit breast 
cancer growth and tumorigenesis. Breast Cancer Res. 2005;7:R145–55. http://dx.doi.org/10.1186/bcr962
162. Laubreton D, Bay S, Sedlik C, Artaud C, Ganneau C, Dériaud E, Viel S, Puaux AL, Amigorena S, Gérard C, Lo-Man R, Leclerc C. The 
fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-
tumor immunity. Cancer Immunol Immunother. 2016;65:315–25. http://dx.doi.org/10.1007/s00262-016-1802-0
163. Huang C-S, Yu AL, Tseng L-M, Chow LWC, Hou M-F, Hurvitz SA. Randomized phase II/III trial of active immunotherapy with OPT-
822/OPT-821 in patients with metastatic breast cancer. JCO. 2016;34:1003.  
http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.1003
164. Russell SJ, Peng K-W, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30:658–70. http://dx.doi.org/10.1038/nbt.2287
165. Guo ZS, Liu Z, Bartlett DL. Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity. Front 
Oncol. 2014;4:74. http://dx.doi.org/10.3389/fonc.2014.00074
166. Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, McGrath Y, Thomas SK, Thornton M, Bullock P, Love CA, Coffin RS. 
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 
2003;10:292–303. http://dx.doi.org/10.1038/sj.gt.3301885
167. Merrick AE, Ilett EJ, Melcher AA. JX-594, a targeted oncolytic poxvirus for the treatment of cancer. Curr Opin Investig Drugs. 
2009;10:1372–82.
168. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer 
immunotherapy. Nat Rev Cancer. 2008;8:299–308. http://dx.doi.org/10.1038/nrc2355
169. Mitchison NA. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells 
in conferring immunity by adoptive transfer. J Exp Med. 1955;102:157–77. http://dx.doi.org/10.1084/jem.102.2.157
170. Borberg H, Oettgen HF, Choudry K, Beattie EJ. Inhibition of established transplants of chemically induced sarcomas in syngeneic 
mice by lymphocytes from immunized donors. Int J Cancer. 1972;10:539–47.
171. Bernstein ID. Passive transfer of systemic tumor immunity with cells generated in vitro by a secondary immune  
response to a syngeneic rat gross virus-induced lymphoma. J Immunol. 1977;118:122–8.  
http://www.jimmunol.org/content/118/1/122.long
172. Cheever MA, Greenberg PD, Fefer A. Tumor neutralization, immunotherapy, and chemoimmunotherapy of a Friend leukemia 
with cells secondarily sensitized in vitro: II. Comparison of cells cultured with and without tumor to noncultured immune cells.  
J Immunol. 1978;121:2220–7.
173. Strausser JL, Mazumder A, Grimm EA, Lotze MT, Rosenberg SA. Lysis of human solid tumors by autologous cells sensitized in 
vitro to alloantigens. J Immunol. 1981;127:266–71. https://link.springer.com/content/pdf/10.1007/BF00199454.pdf
174. Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA. Lysis of fresh and cultured autologous tumor by human 
lymphocytes cultured in T-cell growth factor. Cancer Res. 1981;41:4420–25.  
http://cancerres.aacrjournals.org/content/41/11_Part_1/4420.long
175. Yron I, Wood TA, Spiess PJ, Rosenberg SA. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells 
infiltrating syngeneic solid tumors. J Immunol. 1980;125:238–45. http://www.jimmunol.org/content/125/1/238.long
Nakasone ES, Hurvitz SA, McCann KE. Drugs in Context 2018; 7: 212520. DOI: 10.7573/dic.212520 20 of 21
ISSN: 1740-4398
REVIEW – Harnessing the immune system in the battle against breast cancer drugsincontext.com
176. Rosenstein M, Eberlein T, Kemeny MM, Sugarbaker PH, Rosenberg SA. In vitro growth of murine T cells. VI. Accelerated skin graft 
rejection caused by adoptively transferred cells expanded in T cell growth factor. J Immunol. 1981;127:566–71. 
http://www.jimmunol.org/content/127/2/566.long
177. Mazumder A, Rosenberg SA. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases 
by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med. 1984;159:495–507. 
http://jem.rupress.org/content/jem/159/2/495.full.pdf
178. Rosenberg SA. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2. J Biol Response Mod. 
1984;3:501–11.
179. Okuno K, Takagi H, Nakamura T, Nakamura Y, Iwasa Z, Yasutomi M. Treatment for unresectable hepatoma via selective hepatic 
arterial infusion of lymphokine-activated killer cells generated from autologous spleen cells. Cancer. 1986;58:1001–6.
180. Schoof DD, Gramolini BA, Davidson DL, Massaro AF, Wilson RE, Eberlein TJ. Adoptive immunotherapy of human cancer using 
low-dose recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res. 1988;48:5007–10.
181. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA. 
Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the 
treatment of patients with advanced cancer. J Natl Cancer Inst. 1993;85:622–32.
182. West WH. Continuous infusion recombinant interleukin-2 (rIL-2) in adoptive cellular therapy of renal carcinoma and other 
malignancies. Cancer Treat Rev. 1989;16 Suppl A:83–9.
183. Sparano JA, Fisher RI, Weiss GR, Margolin K, Aronson FR, Hawkins MJ, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH. Phase II trials 
of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, 
and pancreas and other tumors. J Immunother Emphasis Tumor Immunol. 1994;16:216–23.
184. Gharib M, Mainguené C, Tamboise E, Tamboise A, Beaupain R. Lymphokine-activated killer cells induce differentiation in MCF-7 
breast carcinoma nodules but not in mastosis nodules maintained in three-dimensional culture. Tumour Biol. 1994;15:90–100. 
https://dx.doi.org/10.1159/000217879
185. Cardillo M, Yankelevich B, Mazumder A, Lupu R. Heregulin induces increase in sensitivity of an erbB-2-overexpressing breast 
cancer cell type to lysis by lymphokine-activated killer cells. Cancer Immunol Immunother. 1996;43:19–25. 
https://link.springer.com/content/pdf/10.1007/s002620050298.pdf
186. Assadipour Y, Zacharakis N, Crystal JS, Prickett TD, Gartner JJ, Somerville RPT, Xu H, Black MA, Jia L, Chinnasamy H, Kriley I, Lu L, 
Wunderlich JR, Zheng Z, Lu YC, Robbins PF, Rosenberg SA, Goff SL, Feldman SA. Characterization of an immunogenic mutation 
in a patient with metastatic triple-negative breast cancer. Clin Cancer Res. 2017;23:4347–53.  
http://dx.doi.org/10.1158/1078-0432.CCR-16-1423
187. Parkhurst M, Gros A, Pasetto A, Prickett T, Crystal JS, Robbins P, Rosenberg SA. Isolation of T-cell receptors specifically reactive 
with mutated tumor-associated antigens from tumor-infiltrating lymphocytes based on CD137 expression. Clin Cancer Res. 
2017;23:2491–505. http://dx.doi.org/10.1158/1078-0432.CCR-16-2680
188. Zacharakis N, Trebska-McGowan K, Somerville R, Lu Y-C, Pasetto A, Black M, Chinnasamy H, Xu H, Gartner JJ, Prickett TD,  
Robbins PF, Rosenberg SA, Goff SL, Feldman SA. Abstract 4982: Regression of metastatic breast cancer after adoptive cell 
transfer of tumor infiltrating lymphocytes and checkpoint blockade. Cancer Res. 2017;77:4982.  
http://dx.doi.org/10.1158/1538-7445.AM2017-4982
189. Abate-Daga D, Davila ML. CAR models: next-generation CAR modifications for enhanced T-cell function. Mol Ther Oncolytics. 
2016;3:16014. http://dx.doi.org/10.1038/mto.2016.14
190. Stancovski I, Schindler DG, Waks T, Yarden Y, Sela M, Eshhar Z. Targeting of T lymphocytes to Neu/HER2-expressing cells using 
chimeric single chain Fv receptors. J Immunol. 1993;151:6577–82. http://www.jimmunol.org/content/151/11/6577.long
191. Sun M, Shi H, Liu C, Liu J, Liu X, Sun Y. Construction and evaluation of a novel humanized HER2-specific chimeric receptor. Breast 
Cancer Res. 2014;16:R61. http://dx.doi.org/10.1186/bcr3674
192. Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, Sadelain M, Eshhar Z, Rosenberg SA, Morgan RA. A herceptin-
based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and 
antitumor activity. J Immunol. 2009;183:5563–74. http://dx.doi.org/10.4049/jimmunol.0900447
193. Nakazawa Y, Huye LE, Salsman VS, Leen AM, Ahmed N, Rollins L, Dotti G, Gottschalk SM, Wilson MH, Rooney CM. PiggyBac-
mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol 
Ther. 2011;19:2133–43. http://dx.doi.org/10.1038/mt.2011.131
194. Davis ZB, Felices M, Verneris MR, Miller JS. Natural killer cell adoptive transfer therapy: exploiting the first line of defense against 
cancer. Cancer J. 2015;21:486–91. http://dx.doi.org/10.1097/PPO.0000000000000156
195. Shenouda MM, Gillgrass A, Nham T, Hogg R, Lee AJ, Chew MV, Shafaei M, Aarts C, Lee DA, Hassell J, Bane A, Dhesy-Thind S, 
Ashkar AA. Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against 
breast cancer cell lines and patient-derived tumours. Breast Cancer Res. 2017;19:76. http://dx.doi.org/10.1186/s13058-017-0867-9
Nakasone ES, Hurvitz SA, McCann KE. Drugs in Context 2018; 7: 212520. DOI: 10.7573/dic.212520 21 of 21
ISSN: 1740-4398
REVIEW – Harnessing the immune system in the battle against breast cancer drugsincontext.com
196. Schönfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, Nowakowska P, Bönig H, Köhl U, Kloess S, Köhler S, 
Holtgreve-Grez H, Jauch A, Schmidt M, Schubert R, Kühlcke K, Seifried E, Klingemann HG, Rieger MA, Tonn T, Grez M, Wels WS. 
Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther. 
2015;23:330–8. http://dx.doi.org/10.1038/mt.2014.219
197. Sahm C, Schönfeld K, Wels WS. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-
modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol Immunother. 2012;61:1451–61.  
http://dx.doi.org/10.1007/s00262-012-1212-x
198. Coveney E, Wheatley GH, Lyerly HK. Active immunization using dendritic cells mixed with tumor cells inhibits the growth of 
primary breast cancer. Surgery. 1997;122:228–34. 
https://www.researchgate.net/publication/10707410_Active_Immunization_Using_Dendritic_Cells_Mixed_With_Tumor_Cells_
Inhibits_The_Growth_Of_Lymphomas
199. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after 
vaccinations with peptide-pulsed dendritic cells. Blood. 2000;96:3102–8. 
http://www.bloodjournal.org/content/96/9/3102.long?sso-checked=true
200. Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Schlom J, Ryback ME, Lyerly HK. A Phase I study of active 
immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients 
with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res. 1999;5:1331–8. 
http://clincancerres.aacrjournals.org/content/5/6/1331.long
201. Chen Y, Emtage P, Zhu Q, Foley R, Muller W, Hitt M, Gauldie J, Wan Y. Induction of ErbB-2/neu-specific protective and therapeutic 
antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. 
Gene Ther. 2001;8:316–23. http://dx.doi.org/10.1038/sj.gt.3301396
202. Pecher G, Häring A, Kaiser L, Thiel E. Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. 
Cancer Immunol Immunother. 2002;51:669–73. http://dx.doi.org/10.1007/s00262-002-0317-z
203. Gong J, Avigan D, Chen D, Wu Z, Koido S, Kashiwaba M, Kufe D. Activation of antitumor cytotoxic T lymphocytes by fusions of 
human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA. 2000;97:2715–8.  
http://dx.doi.org/10.1073/pnas.050587197
204. Zhang Q, Liu X-Y, Zhang T, Xhang X-F, Xhao L, Long F, Liu Z-K, Wang E-H. The dual-functional capability of cytokine-induced killer 
cells and application in tumor immunology. Hum Immunol. 2015;76:385–91. http://dx.doi.org/10.1016/j.humimm.2014.09.021
205. Ren J, Di L, Song G, Yu J, Jia J, Zhu Y, Yan Y, Jiang H, Liang X, Che L, Zhang J, Wan F, Wang X, Zhou X, Lyerly HK. Selections of 
appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-
induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such 
contentious therapeutic preferences. Clin Transl Oncol. 2013;15:780–8. http://dx.doi.org/10.1007/s12094-013-1001-9
206. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 
2017;168:707–23. http://dx.doi.org/10.1016/j.cell.2017.01.017
207. Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, Nisenbaum H, Pasha T, Xu M, Fox KR, Weinstein S, Orel SG, 
Vonderheide R, Coukos G, DeMichele A, Araujo L, Spitz FR, Rosen M, Levine BL, June C, Zhang PJ. Targeting HER-2/neu in early 
breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 2007;67:1842–52.  
http://dx.doi.org/10.1158/0008-5472.CAN-06-4038
208. Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A. Phase 2 study of pembrolizumab (pembro) monotherapy for previously 
treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. JCO. 2017;35:1008.  
http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.1008
209. Schmid P, Park YH, Muñoz-Couselo E, Kim S-B, Sohn J, Im S-A. Pembrolizumab (pembro) + chemotherapy (chemo) as 
neoadjuvant treatment for triple negative breast cancer (TNBC): preliminary results from KEYNOTE-173. JCO. 2017;35:556.  
http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.556#affiliationsContainer
